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COMPUTATIONAL APPROACHES TO DELINEATE TRANSCRIPTIONAL AND
FUNCTIONAL HETEROGENEITY IN PANCREATIC CANCER

Sanjana Srinivasan, B.Sc., M.P.H.

Advisor: Dr. Giulio Dreatta, M.D., Ph.D.
Abstract:
Pancreatic ductal adenocarcinoma (PDAC) is an incurable disease characterized
by poor survival, dense desmoplastic stroma and activating mutations in KRAS (>90%).
These tumors are highly complex ecosystems composed of molecularly distinct subpopulations that exhibit a spectrum of genetic features and associated phenotypes.
Despite recent advances in the transcriptomic characterization of PDAC into at least two
tumor subtypes, this alone has been insufficient to define more specific patterns of
oncogenic dependency. To fully leverage advancements in next generation sequencing
and functional genomics, we have sought to establish computational methodologies to
aid in refined target discovery, and to develop a novel platform to comprehensively
characterize the transcriptional heterogeneity of PDAC. Specifically, focusing on a large
PDAC PDX cohort, we focused on a) establishing a PDAC co-expression network to
serve as a foundation for quantifying disease diversity within the cohort, while in parallel
b) optimizing an analytical approach to allow for in vivo CRISPR-Cas9 functional
genomics using select models from the cohort. Applying and integrating this novel
computational methodology, we integrated CRISPR-based co-dependency annotations
with a disease-specific co-expression network developed from patient-derived models to
establish a framework to quantitatively associate gene-cluster patterns with genetic
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vulnerabilities. We defined multiple prominent anti-correlating gene-cluster signatures
and pathway-specific dependencies, both across genetically distinct PDAC models and
intratumorally at the single-cell level. This characterization of intratumoral cluster
representation was accomplished through a novel adaptation of network signatures for
single-cell analysis. Of these network-defined cluster trends, one differential signature
recapitulated the characteristics of classical and basal-like PDAC molecular subtypes on
a continuous scale, which we validated using direct capture Perturb-seq. Our results
demonstrate the utility of this integrated platform as a quantitative approach for
characterizing specific genetic dependencies within defined molecular contexts
represented in PDAC, with the potential to guide future clinical positioning for targeted
therapeutics while also considering a constantly evolving intratumoral heterogeneity.
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Chapter 1: Introduction
Pancreatic Ductal Adenocarcinoma (PDAC), the most common form of pancreatic
cancer, is an aggressive malignancy typically diagnosed at an advanced stage and
resistant to most forms of treatment1. PDAC is the fourth most common cause of cancer
related death in the United States2 and has an extremely poor prognosis - frequently
detected as advanced non-localized tumors with a five-year survival rate of ≤10%1. The
main factor influencing the survival outcome is the stage of tumor at diagnosis. Only 1020% of patients present with surgically resectable tumors at the time of diagnosis, while
most patients present with locally advanced disease, unresectable tumors or
metastases3.
1.1: PDAC Epidemiology
Epidemiological studies have identified risk factors for pancreatic cancer including
cigarette smoking, type 2 diabetes, high alcohol consumption, being overweight or obese,
and a family history of pancreatic cancer2. A history of chronic pancreatitis is also found
to increase the risk of developing pancreatic cancer later in life4. Additionally, 80-90% of
patients diagnosed with pancreatic cancer are over the age of 55, with the majority of
patients being diagnosed in their 70s5, and a slightly higher incidence in men compared
to women5. Within the United States, African Americans have a 50%-90% higher risk of
pancreatic cancer compared to Caucasian Americans, with Pacific Islanders and Asian
Americans having the lowest risk5. The higher rate in African Americans is possibly due
to higher prevalence of lifestyle factors listed above that increase the risk for pancreatic
cancer, but gene by environment interactions have also been proposed to play a role1.
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Inherited genetic syndromes can also increase risk for PDAC, including hereditary breast
and ovarian cancer syndrome involving mutations in the BRCA1, BRCA2 and/or PALB2,
familial atypical multiple mole syndrome caused by mutations in p16/CDKN2A, and Lynch
syndrome, which is also implicated in familial colorectal cancer incidence (as reviewed by
McGuigan, et al.2018)2.
1:2: PDAC Genetics and Biology
The pancreas consists of exocrine (acinar), epithelial (ductal) and acinar (a, b, d,
e) cells. The acinar cells present with a high degree of plasticity and go through a process
called acinar-to-ductal metaplasia (ADM) - whereby acinar cells transdifferentiate into a
more ductal morphology and phenotype under conditions like inflammation or stress6,7.
Acinar cells undergoing ADM become more prone to oncogenic events, defining the
genetic progression model of PDAC carcinogenesis8. These events include activating
mutations in KRAS on chromosome 12p, which transforms mutated tissue into pancreatic
intraepithelial neoplasia (PanIN). These lesions tend to be largely asymptomatic in nature,
with minimal disruption of pancreatic function in early stages. PanINs were previously
classified into three grades: PanIN1A (flat lesion) and PanIN1B (micropapillary type)
which display low grade dysplasia, PanIN2 which exhibits loss of polarity, nuclear
crowding, cell enlargement and papillary formation, and finally PanIN3, which present as
advanced lesions with nuclear atypia, luminal necrosis, and epithelial cell budding into
the ductal lumen9. Currently, the PanIN classification is divided into low grade (PanIN1
and PanIN2) and high grade (PanIN3)10.
During PDAC pathogenesis, the progression into higher grade PanINs are
accompanied with sequential loss of tumor suppressor genes. Following activating
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mutations in KRAS, loss of function mutations in tumor suppressor TP53, followed by
CDKN2A, and SMAD4, which make up the most frequent alterations/mutations in
PDAC11. In addition to these four prominent mutations, advancement in sequencing and
genetic techniques have provided further insight into the genetic complexity of PDAC,
with an average of 63 genetic aberrations in an individual tumor12. Large scale genomic
studies have also characterized a long tail of mutations, each with prevalence in less than
10% of patients, including RNF43, ARID1A, TGFβR2, GNAS, RREB1, and PBRM. In
KRAS wild type tumors, genes such as GNAS, BRAF, CTNNB1, which were found to be
mutated12. These mutations lead to dysregulations of key pathways and processes
including activation of RAS-ERK signaling, loss of the G1/S checkpoint, NOTCH
signaling, Hedgehog signaling, Wnt/β-catenin, axon guidance, and chromatin remodeling
(as reviewed by Ying, et al)13. While over 90% of patients have KRAS mutations,
additional amplifications accelerate the tumor promoting the potential for lesions even
more. Apart from mutations, AKT2 overexpression and PI3K activity that is elevated in
PDAC leads to increased tumor cell proliferation and survival14,15. In addition to this,
impaired DNA damaged repair (DDR) genes BRCA1/2, ATM etc. lead to an increase in
microsatellite instabilities13. Epigenetic regulatory circuits including DNA methylation and
histone post translational modifications are also dysregulated in PDAC, which leads to
further repression of tumor suppressor genes and upregulation of oncogenes16.
Another crucial hallmark of PDAC is the dense desmoplastic stroma, which
comprises up to 90% of the tumor volume. This stroma is made up of extracellular matrix
(ECM), vasculature and cancer associated fibroblasts (CAFs)17. CAFs have distinctive
subtypes with myofibroblastic or inflammatory phenotypes. CAFs are hypothesized to
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originate from pancreatic stellate cells that are activated upon injury or chronic
inflammation, at which point they deposit large amounts of ECM including laminins,
fibronectins, collagens and hyaluronan into the space surrounding tissues18,19. The
stromal component is purported to be responsible for challenges in drug delivery and
alterations of metabolic features of the tumor20. However, studies focused on targeting
the stroma have either resulted in non-significant results on decreasing the tumor mass,
or in more aggressive forms of PDAC21. In addition to stroma, the PDAC
microenvironment is extremely hypoxic due to desmoplasia induced hypovascularization,
which further activates pancreatic stellate cells22. This hypoxic environment, coupled with
the dense desmoplasia acts as a barrier to both proliferation of treatment, and also
prevents T cell infiltration23. Macrophages within the microenvironment are also
hypothesized to create an immunosuppressive and pro-angiogenic environment, blocking
T cell entry into the microenvironment, and supporting PDAC progression24.
PDAC is also characterized by early progression to metastasis25. Common sites of
metastases include the peritoneum, liver, other gastrointestinal organs, lungs, and the
nervous system. Metastases appear to be a clonal process – with the primary tumor being
composed of subclones exhibiting variable metastatic potential25. A crucial component of
metastases in PDAC is epithelial to mesenchymal (EMT) transition, especially
mesenchymal driver gene ZEB9.
1.3: PDAC Management and Treatment
At this time, surgical resection is the only treatment for pancreatic cancer that is
considered potentially curable26. Pancreatico-duodenectomy, also known as the
Whipple’s procedure, distal or total pancreatectomy are the main surgical options for

4

pancreatic cancer. However, only 10-20% of patients present with surgically resectable
disease at the time of diagnosis3,26. Following curative surgery, the median survival of
patients 15-20 months and a five-year survival rate of 8-15%26. However, 69-75% of
patients who undergo surgical develop recurrent tumor disease within 2 years, and 8090% relapse within 5 years27.
Adjuvant chemotherapy with fluorouracil and folinic acid showed significantly
improved overall survival and five-year survival rate compared to patients who did not
receive

chemotherapy

after

surgery28.

Similarly,

adjuvant

chemotherapy

with

gemcitabine, compared to surgery alone, has been found to increase disease -survival
time, resulting in a statistically significant, albeit limited increase in survival from 20
months to 23 months29. Studies evaluating the effectiveness of fluorouracil plus folinic
acid, compared to gemcitabine, demonstrated no significant differences in survival, but
significantly more adverse events in the fluorouracil plus folinic acid condition30.
Combination therapy of capecitabine and gemcitabine showed a slight increase in
adverse events but significant increase in survival compared to gemcitabine alone28.
Other chemotherapies such as a combination treatment – mFOLFIRONOX (fluorouracil,
folinic acid, irinotecan and oxaliplatin) compared to gemcitabine have demonstrated
increased disease-free survival as well as overall survival. mFOLFIRINOX was
associated with increased adverse events, but toxicities were manageable depending on
the age and physical fitness of the patient31. The current recommended standard of care
post-surgery is mFOLFIRINOX in patients physically fit enough to tolerate adverse
events, or combination gemcitabine and capecitabine treatment in less fit patients26,32,33.
Medical management in metastatic PDAC patients involves symptom control, pain
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management, and palliative chemotherapy with FOLFIRONOX (mFOLFIRINOX with 5fluorouracil) or gemcitabine34.
Targeted therapies and precision medicine in PDAC are still in its infancy. Erlotinib,
an EGFR inhibitor, developed and approved to treat non-small cell lung cancer was one
of the first attempts at introducing targeted therapies within PDAC35. Erlotinib was
incorporated in combination with gemcitabine as part of a first line chemotherapy regimen.
While this resulted in a statistically significant increase in overall survival compared to
gemcitabine alone, this was only an increase of two weeks36. While this was intended to
be a targeted therapy, the trial did not stratify patients based on EGFR overexpression or
mutation36. In contrast, an ongoing clinical trial, POLO trial, is a targeted therapy based
on stratification of patients with germline BRCA1 or BRCA2 mutations (approximately 2%
of patients)37. In this trial, patients with metastatic PDAC patients, were treated with the
PARP inhibitor Olaparib as maintenance therapy as opposed to gemcitabine. Initial
reports showed a significant improvement in progression-free survival in the Olaparib
treatment group compared to the gemcitabine placebo group (7.4 months versus.
3.8 months, p = 0.004) with mild indications of toxicity. The latest update on the trial was
discussed at the ASCO Gastrointestinal Cancers Symposium in January 2021.
Unfortunately, these results indicated that there was no statistically significant difference
in survival in patients in the Olaparib arm compared to the placebo38.
In order to better understand the heterogeneity in PDAC that can be clinically
actionable for targeted therapy, the field has sought to expand into categorizing the
disease into clinically prognostic subtypes.
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1.4: PDAC Subtypes
Recent efforts in PDAC molecular subtyping have better characterized disease
heterogeneity using transcriptomic signatures associated with clinical features, which can
be used to define multiple PDAC subtypes. Here I will describe the most widely used and
reproduced subtyping systems in PDAC, which primarily rely on quantifying
transcriptional signatures.
1.4.1: Collisson Classification
The Collisson classification was the first major attempt at PDAC molecular
subtyping method to be widely used20. Using transcriptional profiles from primary PDAC
samples, along with mouse and human PDAC cell lines, variable gene signatures using
non-negative matrix factorization (NMF) on microarray samples to identify gene signature
clusters that show differential expression. With these gene signatures, they performed
consensus clustering to identify three subtypes – classical, quasi-mesenchymal and
exocrine-like. The classical subtype demonstrated high expression of adhesionassociated genes and epithelial genes, while the quasi-mesenchymal subtype highly
expressed genes associated to a mesenchymal profile, and the exocrine-like subtype
exhibited a high expression of tumor-cell derived digestive enzyme genes20. Within this
system, patients whose tumors were classified as classical fared better in terms of
survival compared to patients classified as quasi-mesenchymal. In cell lines, classical
cells have shown relatively higher dependence on KRAS over quasi-mesenchymal cell
lines20. Additionally, classical cell lines show greater sensitivity to Erlotinib, an EGFR
inhibitor, compared to quasi-mesenchymal cell lines, which showed greater sensitivity to
gemcitabine20.
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1.4.2: Bailey Classification
Bailey, et al, also defined a subtype classification for PDAC based on the analysis
of a cohort of PDAC tumors with high epithelial content (> 40%) and identified four unique
subtypes – squamous, pancreatic progenitor, immunogenic and endocrine exocrine or
ADEX. This was based on variable expression of transcription factors and downstream
targets39. Squamous tumors harbored mutations in TP53, KDM6A and upregulated
hypermethylated pancreatic endodermal cell fate determining genes. Progenitor tumors
overexpressed genes involved in early pancreatic development. Immunogenic tumors
upregulated genes involved in immune pathways, and the ADEX tumors highly expressed
KRAS activation genes, and both exocrine and endocrine differentiation genes. These
subtypes

corresponded

with

specific

histologies

–

squamous

tumors

with

adenosquamous carcinoma, progenitor and immunogenic with mucinous non-cystic
adenocarcinoma, and ADEX with rare acinar cell carcinoma. The squamous subtype was
shown to have the poorest survival overall39.
1.4.3: Moffitt Classification
In 2015, Moffitt, et al developed another classification scheme for PDAC by
focusing on deconvoluting tumor cell intrinsic gene expression signatures40. Using a
cohort of patient and PDX PDAC tumors samples, they applied a virtual microdissection
approach to computationally separate gene expression signals arising from the stroma
and tumor microenvironment. Using consensus clustering, they identified two distinct
stromal signatures – “activated” and “normal”. The normal stromal signature was
characterized by expression of key marker genes of pancreatic stellate cells, whereas the
activated stromal signature was characterized by genes associated with macrophages,
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and genes involved in tumor promotion, including members of the Wnt family of genes.
They also described two distinct cell intrinsic subtypes – classical and basal-like. The
basal-like subtype was so called due to the similarity to the basal subtypes in bladder and
breast cancers. Patients with basal-like tumors have decreased survival compared to
classical tumors40 Basal-like tumors have responded more favorably to adjuvant
chemotherapy than classical tumors, but have recently been associated with treatment
resistance to FOLFIRINOX40.
1.4.4: Integrated Analysis of Classifications by the TCGA
The Cancer Genome Atlas (TCGA) consortium applied the clustering techniques
from the Collisson, Moffitt, and Bailey studies on their large cohort of patient PDAC
tumors12. While they were able to recapitulate Collisson’s three subtypes, Bailey’s four
subtypes and Moffitt’s basal-like and classical subtypes, they found that only Moffitt’s
subtypes were consistently independent of sample purity. Considering only high purity
samples (>30% cellularity), the pancreatic progenitor subtype from Bailey’s classification
and the Collisson classical subtype overlapped with Moffitt’s classical subtype, while the
Bailey squamous subtype and Collisson quasi-mesenchymal subtypes overlapped with
Moffitt basal-like subtypes. The immunogenic and ADEX subtypes were strongly
associated with low purity tumors, suggesting that these subtypes are likely a result of
signals from non-tumor cells. It is hypothesized that the variation in the samples and
analyses used explain the differences in the subtypes, but overlap across classification
methods15.
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1.4.5: Puleo Classification
Puleo et al, released a classification based on independent component analysis of
PDAC

tumors

with

deconvolution

of

normal,

microenvironment

and

tumor

compartments41. They identified two tumor subtypes, which recapitulated the Moffitt
classical and basal-like subtypes. They also identified stromal components, activated
stroma component – with overexpression of extracellular matrix organization, collagen
formation, and focal adhesion. The second stromal component was the inflammatory
stroma component – with high expression of IL-6 and other markers of inflammation. This
classification also reported that the ADEX subtype previously described emerged from
normal cell contamination. They ultimately identified five subtypes from unsupervised
clustering of their entire cohort – “pure” classical and basal-like with signal emerging
primarily from the tumor, and three microenvironment subtypes – immune classical,
stroma activated and desmoplastic. The authors argue that this classification system,
which is recapitulative of the Moffitt subtypes, provides more clinical value by
incorporating microenvironmental heterogeneity41.
1.4.6: COMPASS Trial: Toronto Classification
Most recently, researchers leading the COMPASS trial for PDAC patients with
advanced disease addressed two pressing issues facing PDAC subtyping – first, lack of
accurate characterization of unresectable, advanced tumors, which make up the majority
of patients in clinic, and second, low cellularity of samples42. Here, over 200 PDAC tumor
samples were collected using laser capture microdissection – resulting in a minimum of
80% cellularity. Using NMF on RNAseq performed on these samples, they defined the
Toronto classification, and identified five subtypes labeled “basal-like A”, “basal-like B”,
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“classical-A”, “classical-B” and a novel subtype that was previously inconsistently
classified due to multiple gene expression signatures, termed “hybrid”42. They found that
classical A/B tumors were more likely to be early stage tumors, with basal A tumors
making up a large portion of stage IV tumors. Furthermore, Moffitt basal-like tumors
showed high association with the basal-like B and hybrid subtypes. In addition to
identifying the hybrid subtype in bulk tumors – tumors that show expression of both
classical and basal-like signatures, they also identified that classical and basal-like cells
exist intratumorally within the same tumor – resulting in hybrid tumors at the bulk scale42.
1.4.7: Current Consensus in PDAC Subtyping
Integration of these subtypes has given rise to a general consensus in the field of
PDAC subtyping of two overarching cell intrinsic subtypes – the classical/progenitor
subtype and the basal-like/squamous subtype39,12,43. However, despite these advances,
and associations being drawn in difference in response to treatment, transcriptomic
subtyping within PDAC is still in its early stages. It has not yet been applied to identify
potential avenues for targeted therapy. Subtypes are not currently widely assessed in
clinical care, and are not used to inform on choice of treatment. Moreover, clonal and subclonal evolution as well as therapeutic intervention can result in molecular signatures that
change the original subtype classification, highlighting the relevance of intratumoral
molecular and functional heterogeneity that underlies high-level subtype groupings41,42.
1.5: Dissertation Objective
Evaluation of the mutational and transcriptional landscape of PDAC has revealed
a wealth of knowledge that has served as the foundation for further biological investigation
about the genes and signaling pathways relevant in tumor maintenance and progression.
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In addition to this, several groups have developed computational tools to identify subtypes
of PDAC using mutational signatures and transcriptomic analyses in both patient and
PDX models. Despite these biological and computational characterization efforts,
targeted

therapy

positioning

in

these

tumors

remains

suboptimal

and

subsequently the clinical prognosis for these patients remains dismal. So far, largescale subtyping and characterization efforts based on statistical and bioinformatics
approaches

centered

on

transcriptomic

and

mutational

landscapes.

These

characterization strategies serve as an indirect measure of tumor dependency, and have
been insufficient to stratify and define pancreatic cancer on a patient-by-patient or tumorby-tumor basis.
My long-term goal is to develop translational computational platforms for PDAC
that enable disease characterization and patient stratification that will inform on potential
avenues for therapeutic intervention. The objective of this dissertation is to establish
computational methodologies that will lead to better target discovery and identification
using functional genomics approaches and to develop a novel platform that will
characterize the transcriptional heterogeneity of PDAC.
To this end, the focus of my research and this research is centered around (1)
developing appropriate analytical tools for in vivo and targeted library screens conducted
on PDAC models (2) quantifying PDAC transcriptional diversity using a novel networkbased approach to capture continuous patterns of heterogeneity (3) adapt our networkbased approach to single cell RNAseq samples across PDAC patient derived xenograft
models and clinical core needle biopsy samples to recapitulate continuous intratumoral
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heterogeneity and (4) anchor genetic dependencies within our transcriptional network to
inform on subtype specific vulnerabilities intratumorally.

Taken together, these efforts: a) provide an accessible framework to serve as a
discovery and hypothesis generation platform, b) allow comprehensive model
characterization of functional genomics inferred oncogenic signaling, c) stratify
tumors and models in terms of survival based on their enrichment, and d) serve as
an avenue to support better clinical positioning of targeted therapies for patients
with PDAC.
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Chapter 2: Materials and Methods
PDX models and Sequencing (RNA and Whole Exome)
A total of 48 models were utilized in this paper. PDAC PDX models were obtained
from the labs of Dr. Michael Kim (Department of Surgical Oncology, MD Anderson Cancer
Center) and Dr. Scott Lowe (Memorial Sloan Kettering Cancer Center)44,45. PDXs were
propagated and maintained in NOD scid gamma (NSG) mice carrying NOD.CgPrkdcscid Il2rgtm1Wjl/SzJ (Jackson Labs).
PDX Sequencing
Whole exome library preparation and sequencing
Whole exome sequencing (WES) libraries were prepared using the Agilent
SureSelect XT library preparation kit in accordance with the manufacturer’s
instructions. Briefly, DNA was sheared using a Covaris LE220. DNA fragments were endrepaired, adenylated, ligated to Illumina sequencing adapters, and amplified by
PCR. Exome capture was performed using the Agilent SureSelect XT v4 51Mb capture
probe set and captured exome libraries were enriched by PCR. Final libraries were
quantified using the KAPA Library Quantification Kit (KAPA Biosystems), Qubit
Fluorometer (Life Technologies) and Agilent 2100 BioAnalyzer and were sequenced on
an Illumina HiSeq2500 sequencer using 2 x 125bp cycles. Base calling and filtering were
performed using current Illumina software and adapters were trimmed using Trim Galore
[55]. Sequences were aligned to both NCBI genome human build 37 and mouse build 38
using Burrows-Wheeler Aligner46; identified mouse reads were removed from the original
FASTQs and then the files were realigned again to NCBI build 37 using BWA. Picard was
used to remove duplicate reads (http://picard.sourceforge.net); base quality scores were
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recalibrated using GATK47. Assessment of reads that do not align fully to the reference
genome was performed, locally realigning around indels to identify putative insertions or
deletions in the region. Variants were called using GATK HaplotypeCaller, which
generates a single-sample GVCF. To improve variant call accuracy, multiple singlesample GVCF files were jointly genotyped using GATK GenotypeGVCFs, which
generates a multi-sample VCF. Variant Quality Score Recalibration (VQSR) was
performed on the multi-sample VCF, which adds quality metrics to each variant that can
be used in downstream variant filtering.
RNA library preparation and sequencing
RNA sequencing libraries were prepared using the Illumina TruSeq Stranded
mRNA sample preparation kit in accordance with the manufacturer’s instructions. Briefly,
100ng of total RNA was used for purification and fragmentation of mRNA. Following
conversion of mRNA to cDNA, DNA was adenylated, ligated to Illumina sequencing
adapters, and amplified by PCR (using 10 cycles). Final libraries were quantified using
the KAPA Library Quantification Kit (KAPA Biosystems), Qubit Fluorometer (Life
Technologies) and Agilent 2100 BioAnalyzer and were sequenced on an Illumina
HiSeq2500 sequencer (v4 chemistry) using 2 x 50bp cycles. Base calling and filtering
were performed using current Illumina software. Reads were aligned to a joint index of
NCBI genome human build 37 and mouse build 38 with STAR aligner48. Reads that map
uniquely and unambiguously to the mouse genome were removed from the FASTQ files
and then the files (containing unmapped reads and reads mapped at least once to the
human reference) were remapped to GRCh37 using STAR aligner and Gencode 19
annotation. Gene expression quantification was performed with featureCounts
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(http://bioinf.wehi.edu.au/featureCounts/). Genes with raw read counts present in less
than 20% of samples were removed from further analysis, and log normalized counts
were generated on the 14175 filtered genes using DESeq49.
Cell Culture
PDX cell lines were seeded in treated tissue-culture plates (Corning) in DMEM/F12
medium (Gibco) supplemented with 10% Fetal Bovine Serum (Gibco), Penicillin (50
units/mL) and Streptomycin (50 µg/mL) (ThermoFischer Scientific). Phosphate Buffered
Saline (PBS) was utilized prior to trypsinization and for general cell washing purposes
(Thermo Fisher Scientific). Cells were regularly trypsonized (0.25%, Trypsin-EDTA,
Gibco) prior to reaching 70% - 80% confluence, and maintained on 10 cm and 15 cm
treated tissue-culture dishes (Corning). Viable cells were counted using a Cellometer mini
and 0.2% Trypan Blue staining (Nexcelom).
Design and construction of custom CRISPR Library
The custom CRISPR-Cas9 sgRNA library was constituted by 3,367 sgRNAs and
designed to both incorporate and expand upon the original RNAi-defined targets. The
library was constructed using chip-based oligonucleotide synthesis and cloned into a
pRSG16-U6-sg-HTS6C-UbiC-TagRFP-2A-Puro lentiviral vector (Cellecta) as a pool.
RSA was used to rank essential genes from shRNA screens. Genes were curated based
on RSA < 0.05 and FC < -2 in at least one model (N=100). Curated gene targets were
further annotated by incorporating neighbors with a PPI score ≥ 0.80 (STRING, version
10), and TPM (transcripts per million) > 2 in that model48. In addition, 50 non-essential
genes and 50 essential genes were added to have a final set of 654 genes50.
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CRISPR Cas9 Screening in vivo and in vitro
Using the custom barcodes lentiviral sgRNA library, PDX lines (PATC69,
PATC124, PATC53 and PATC153) containing the lentiCas9-blast vector (addgene,
plasmid #52962) were transduced in vitro using 8 µg/mL Polybrene (Sigma-Aldrich). PDX
lines transduced with Cas9 were constantly kept at 10 µg/mL blasticidin (Thermo Fischer
Scientific). Libraries were transduced at 1000X coverage and a multiplicity of infection
(MOI) of 0.3. Media was replaced after 14 hours, and at 48 hours, and MOI was
confirmed by checking RFP percentage with flow-cytometry 48 hours post-transduction.
Immediately following flow cytometry, 2 ug/mL puromycin (Thermo Fisher) was added to
each transduced cell population for 72 hours. Immediately following puromycin selection,
a Reference population was collected (1000X) and stored at -80 °C. Cells were allowed
to culture for an additional 12 days in order to allow for some initial sgRNA-directed cutting
prior to starting the in vivo screen, to reduce potential noise derived from disproportional
cell doubling following orthotopic implantation. A secondary Reference (1000X), at the
time of injection, was then collected. Remaining cells were split and moved into in vitro
and in vivo settings. Three independent in vitro screens were seeded (1000X) into 15 cm
treated plates (Corning). For in vivo implantation, cells were combined into 1:1
PBS/Growth-Factor Reduced Matrigel (Corning), and injected orthotopically at 1000X
coverage per mouse. Immunodeficient NSG mice were leveraged for in vivo screening.
For in vitro screening populations, cell populations were collected at 10, 20, and 30 days
post injection and secondary Reference collection. For in vivo screening, the entire
pancreas and tumor of each mouse was collected at day 30 post injection. DNA extraction
and barcode library preparation were conducted in similar fashion to the RNAi screens.
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For each condition, cells were lysed using SDS and DNA was sheared using sterile 23gauge 1-inch needles (Becton Dickinson). DNA was isolated using Phenol:Chloroform
extraction and Ethanol precipitation. Nested PCR was utilized to amplify and prepare
barcode populations for NGS (Cellecta).
Network Display
Cytoscape (version 3.7.2) was leveraged for visualization of both the PDAC coexpression network and STRING-anchored co-dependency networks51,52. The PDAC coexpression network was visualized using a Prefuse Force-Directed Layout, with node
color displayed based on Random Walk defined clusters and node size representative of
Betweenness Centrality. For visualization purposes, only nodes with 12 or more edges
are represented, and edges are not displayed in representative co-expression network
figures. For STRING-anchored co-dependency networks, a Perfuse Force-Directed
Layout is also applied, with quantile-normalized Bayes Factors represented as a blue -tored color distribution. For each in vivo and in vitro condition, networks were constructed
for each independent PDX line and then merged for comparison based on overlapping
nodes. All STRING-defined edges were maintained for in vivo and in vitro network
merging.
Clinical correlations with signature
Clinical data from patients corresponding to the PDAC PDX cohort was provided
by the lab of Dr. Eugene Koay53. Differentiation status on 45 models was categorized as
“Poor” and “Moderate” and histology status on 35 models was categorized as
“Locoregional” if the records indicated as “regional” or “locoregional”, and “Distant” if site
was outside the pancreas. Chi square tests were used to evaluate differences between
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the cluster-defined Classical, Quasi-basal and Basal groups as well as the Moffitt binary
classification.
Single Cell Data for PDX-derived Cell Lines
Seurat version 3.154 was used to analyze all single cell analysis. Each of the lines,
PATC124, PATC53 and PATC69 were analyzed separately. PATC53 contained two
replicates, which were merged for analysis. For all PDX cell lines, single cells with a
minimum of 350 expressed genes and less than 10% mitochondrial reads were retained.
Genes expressed in less than 3 cells and mitochondrial genes were removed from further
analysis. The data was log normalized, transformed using the “vst” function with top 2000
variant genes. The total RNA count, cell cycle score and mitochondrial reads were
regressed out. For PATC124, principal-component analysis and uniform manifold
approximation and projection (UMAP) with the first 15 dimensions was performed,
followed by identifying clusters using a resolution of 0.15. For PATC69, principalcomponent analysis and uniform manifold approximation and projection (UMAP) with the
first 15 dimensions was performed, followed by identifying clusters using a resolution of
0.10. PATC53 contained two replicates, which were integrated as one dataset following
normalization and variant stabilization. Total RNA count, cell cycle score and
mitochondrial reads were regressed out of the integrated dataset, and PCA and UMAP
on first 15 dimensions was performed, further identifying clusters using a resolution of
0.10.
Core Needle Biopsy Single Cell Analysis
Seven CNB samples were used – four primary tumors, one liver, lung and vaginal
metastases sample each55. All seven samples were filtered to have a minimum of 350
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expressed genes and less than 25% mitochondrial reads were retained. Similar to the
PDX analysis, genes expressed in less than 3 cells and mitochondrial genes were
removed from further analysis. Each sample was log normalized, transformed using the
“vst” function with top 2000 variant genes. The seven samples were then integrated,
following which, the total RNA count, cell cycle score and mitochondrial reads were
regressed out. Principal-component analysis and UMAP with the first 20 dimensions was
performed, followed by identifying clusters using a resolution of 0.20. Cell types
associated with clusters were identified using established stromal markers56,57 and
epithelial cell markers specific to liver and pancreas55,58,59.
Feature Barcoding Vector
The feature barcode vector (LentiCRISPR-E-10xcs1) was built using the
pLentiCRISPR-v2 (addgene: 52961) as the base vector.

All of the molecular

modifications were performed by Epoch Life Sciences (Missouri City, Tx). The
pLentiCRISPR-v2 was modified to an optimized sgRNA scaffold60 that included the 3’ 10x
capture sequence 1:
(cgtttCagagctaTCGTGgaaaCAGCAtagcaagttaaaataaggctagtccgttatcaacttgaaaaagtggca
ccgagtcggtgcGCTTTAAGGCCGGTCCTAGCAAtttttt);

a

ccdb

bacterial

expression

cassette between the BsmBI restriction sites was introduced to reduce background during
sgRNA cloning and library generation; and an N-terminal Flag-sv40 NLS was added to
Sp. Cas9-nucleoplasmin NLS-P2A-Puro.
Preparation of Feature Barcoded sgRNA Knockout Populations
Lentiviral transductions of four separate feature barcode sgRNA vectors (targeting
ABCG8, ILK, SMAD4 and ZEB1), were conducted on separate cell populations for both
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the PATC69 and PATC53 PDX lines. Lentivirus was concentrated through ultracentrifugation, resuspended in 200 µL of PBS, and stored at -80 °C until use. For each
condition, 1x106 cells were transduced in 10 cm treated plates (Corning) using 8 µg/mL
Polybrene (Sigma-Aldrich). Media was replaced after a 16-hour incubation, and each cell
population was washed with PBS and then placed under puromycin selection for 72
hours. Following selection, all conditions were cultured for 22 days (or 10 days post
“CRISPR Screen Injection point”) to match the in vitro CRISPR screen control-separation
profile at day 10 (Extended Data Figure 2A). Prior to library preparation for scRNAseq,
knockout populations were combined in equal proportion for each PDX line. Library
preparation was conducted on a total of 10,000 cells per PDX line, resulting in an
approximate coverage of 2500 cells per condition.
sgRNA Phenotype Confirmation and Confirmation of Site-Specific Cutting
Utilizing the same feature barcoded populations prepared for scRNAseq, 1500
cells/well were seeded in triplicate in 12 well tissue culture plates (Corning) immediately
following 72 hours of 2 µg/mL Puromycin selection. Cells were then cultured for a
minimum of 10 doublings. Individual plates were then stained with 0.5% crystal violet (in
25% methanol) for 2 hours. Plates were washed in water, dried overnight and then
digitally scanned. After digitally scanning the plates, crystal violet was dissolved in equal
volumes of 1% SDS, and 200 µL of each sample was moved into 96-well plates to
measure absorbance at 570 nm. Relative growth was quantified based on the internal
sgABCG8 negative control. All data was graphed using GraphPad Prism v 8.0.
Puromycin selected cells were collected for Sanger sequencing to confirm sgRNA
induced indel formation relative to non-infected populations. Cell pellets for each sgRNA
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across both PATC69 and PATC53, 1x106 cells each, were isolated at Day 12 and Day 40
for each PDX line (sgRPS27A indels representative at Day 12, all other sgRNAs at Day
40). Cell pellets were centrifuged, washed once with PBS, and frozen at -80 °C. All Sanger
sequenced regions were normalized against respective non-transduced PDX line
populations, 1x106 cells/pellet. Primers for each cut site were developed to allow for 400
- 800 bp products, and primer sites were run on 2% agarose gels and extracted following
amplification. Site-specific sequencing primers were utilized for Sanger sequencing, and
indels distributions were calculated using the Synthego ICE Analysis Tool61.
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Chapter 3: Novel Methodology for Target Library CRISPR Screening
This work is based on efforts outlined in our recent BioRxiv submission “Diversity
Across the Pancreatic Ductal Adenocarcinoma Disease Spectrum Revealed by
Network-Anchored Functional Genomics” by Rose and Srinivasan, et al. (2020), DOI:
https://doi.org/10.1101/2020.09.17.302034. As co-first author, Dr. Johnathon Rose
provided substantial experimental support for this effort, enabling our findings. The
manuscript is currently under review.

Existing methodologies can accurately identify essential genes within CRISPR
screens of large library complexity, however they cannot be applied to small in vivo
libraries due to overfitting these small datasets with limited controls, resulting in a loss of
accuracy. Here, we have modified the currently used Bayesian classifier of gene
essentiality, BAGEL, used to detect context-specific essential genes. Using this adapted
method, Low-Fat BAGEL, we have compared essentiality profiles among PDX models
and within the models by comparing the differentially essential genes in vitro and in vivo.
3.1: CRISPR and its Uses in Functional Genomics
Systematic perturbations of genes, and the subsequent tracking of these genetic
perturbations to observe cellular level dropout, provides a phenotypic readout of causal
genes underlying dependence in a cell and tissue specific manner62,63. Furthermore, the
comprehensive analysis of these genetic dependencies within the backdrop of known
molecular interactions and pathways provides a wider view of the major contributors to
proliferative signaling. The recent discovery and subsequent adaptation of the clustered
regularly interspaced short palindromic repeats associated Cas endonuclease system
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(CRISPR/Cas) technology has enabled high-precision knock-out screens for both arrayed
and pooled settings62. As a result, this recent advancement has vastly propelling the field
of functional genomics forward by providing the capacity for precise systematic genelevel perturbations, using both targeted and whole-genome libraries, to uncover genetic
dependencies in disease models63-65.
The Nobel Prize winning discovery of the CRISPR/Cas system was first described
as a form of adaptive immunity in prokaryotes66. Identified in most species of bacteria and
archaea, it is involved in developing resistance to bacteriophages66. Of the various
systems identified, one of focus and early investment for application in eukaryotic model
systems was the S. pyogenes derived bacterial type II CRISPR system using the Cas9
endonuclease. Adaptation of this system for mammalian cells allows this engineered
Cas9 system to introduce a frameshift mutation into early exon coding regions of specific
genes of interest, resulting in targeted loss of function. Specifically, the Cas9 proteins
generate a double stranded break at a target locus, located three bases upstream of an
“NGG” protospacer adjacent motif (PAM) recognition site at the 3’ end of a 20 -nucleotide
base pair sequence complementary to the short guide RNA (sgRNA). The induced double
stranded break is repaired by non-homologous end joining (NHEJ), which is error prone,
leading to indels. Targeting coding regions thus allows for gene knockout, enabling the
study of gene function in a high-throughput, pooled genome-wide scale to systematically
interrogate function in different biological systems67. The CRISPR/Cas screening system
is a rapidly adapted and evolving mechanism to interrogate genes essential in specific
genetic and disease contexts. Given this, several genome-wide CRISPR/Cas9 screening
libraries have been developed for genetic screening in human cell cultures, mouse and
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other model systems62-65. This system offers an advantage over previously used systems
such as RNA interference by avoiding the off-target effects and incomplete gene
knockdown of the latter system. A typical genome wide CRISPR screening library
consists of either mouse or human coding genes targeting multiple loci, with four to ten
loci us sgRNAs per gene65,68. They are available as either a single plasmid system with
the sgRNA and Cas9 protein on a single vector69, or a two-plasmid system with the sgRNA
and Cas9 protein on separate lentiviral vectors.
High throughput, pooled CRISPR screening consists of designed sgRNAs
synthesized and cloned into a lentiviral library (with or without Cas9) and transduced into
living cells at a low multiplicity of infection (MOI) of 0.3, to prevent the likelihood of multiple
guides integrating into a single cell. Successfully transduced cells are then cultured, and
the integrated sgRNA are replicated along with the rest of the host genome during cell
division. An initial time point (Day 0, immediately following selection) is collected to serve
as a reference population67. To identify essential genes, at least one other subsequent
time point is collected at later doublings for comparison. These two, or more populations
are then compared. Within these screens, the outcome of interest is gene essentiality
within the context of cellular fitness64. If a gene is essential, it is expected that a knock out
of this gene, and depletion of the encoded protein within the cell, would result in
decreased viability of that cell. In a negative selection screen, the later time-points are
compared to the Day 0 timepoint to identify genes that have “dropped out” of the
population. In the case of a certain genetic background or disease, “context essential”
genes are ones whose normal function is required for the continued survival and
proliferation of that cell. Knockout of these genes would result in the phenotype of cell
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death, resulting in a fewer surviving cells with the corresponding sgRNA in the later timepoints compared to Day 0. Thus, the typical statistical readout of CRISPR screens is
foldchange, calculating the relative abundance of guides in the later time-points compared
to the reference population. A major assumption in taking the normalized log foldchange
of sgRNA abundance is that the majority of genes will have no effect or phenotype upon
knockout – resulting in a foldchange centered around 018.
3.2: Analytical Tools in Genome-Wide CRISPR Screening
With the advent of accessible CRISPR/Cas9 screening, there has been a vast
increase in publicly available high-quality screens across various genetic and disease
backgrounds. In turn, this has enabled the development of several new analysis pipelines.
Methods for these large-scale screens involve the typical steps of quantifying sgRNA
abundance by mapping sequencing reads back to the sgRNA library, comparing the later
time-point screens to the reference timepoint to compute relative abundance of each
sgRNA and aggregating the effects of all sgRNAs on a gene-wise scale to understand
the effect of each gene in the library. Here, I will briefly describe a few analytical tools
developed to address the bioinformatic complexity of screening data.
3.2.1: Redundant siRNA Activity (RSA)
This method was initially developed for the analysis of short hairpin RNA (shRNA)
in RNAi screening70. RSA relies on the core principle of negative selection CRISPR
screening – an “hit” or an essential gene would show greater differences in overall
foldchange in the at the endpoint of a screen compared to the reference population. All
targeting guides are ranked by decreasing foldchange between the endpoint to the
reference point. A p value is calculated using a hypergeometric distribution to calculate
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the probability for each gene under the null distribution assuming all guides behave
uniformly. P-values for all guides for a single gene are then used to determine whether
the guides for that gene are significantly higher than the rest of the distribution. While
RSA analysis is robust in shRNA screen analysis, it consistently does not perform as well
with CRISPR screens when compared to methodology designed specifically for these
screens.
3.2.2: MAGeCK
The Model-based Analysis of Genome-wide CRISPR/Cas9 Knockout (MAGeCK)
method was first developed in 2014 by Li et al, and is a widely used analytical tool for
CRISPR screens71. MAGeCK employs a negative binomial distribution similar to RNAseq
analysis platforms such as DESeq249. The variance of median normalized raw sgRNA
counts between the later time-points and control populations is used to calculate a guide
level p value. The Robust Ranking algorithm (RRA) implemented within MAGeCK to
combine the guide level p values to compute a gene level False Discovery Rate (FDR)
using the Benjamini-Hochberg correction for multiple testing. The MAGeCK-RRA method
is designed for both loss-of-function and positive selection gain-of-function screens. The
MAGeCK toolset also contains a version for identifying gene hits across treatment and
drug conditions. This Maximum Likelihood Estimate (MLE) method uses a design matrix
of samples from each condition and extends the negative binomial model to include a
generalized linear model to fit a coefficient at the gene level and compute a p value and
estimated effect size. Like MAGeCK RRA, MLE also computes an FDR and gene hits for
both loss-of-function and gain-of-function screens.

27

3.2.3: CERES
Measurement of gene effect sizes has been found to be confounded by copy
number variations (CNVs) present at the target site of individual guides. By introducing
Cas protein induced cuts, regions with high copy number might have induced an
antiproliferative effect on transduced cells due to DNA damage, rather than context
specific gene essentiality. To address this, the Broad Institute developed a method
termed CERES that computationally corrects for gene variation bias72. CERES was
developed as part of the Achilles/DepMap effort that initially released genome-wide
CRISPR screen data from 342 cancer cell lines, known as the Avana project. CERES
compares the effect of the same guide across all cancer cell lines to normalize per cell
line. While the CERES method successfully reduces the number of false positive hits in
CRISPR screens, it is only applicable in experiments involving multiple cell lines to
compare the effects of genomic amplification. In addition, CERES also requires copy
number profiles for cell lines/models being screened, which can be prohibitive in cases
where this data is not publicly available. A more recent method by investigators at the
Sanger Institute developed a method termed CRISPRCleanR73, aimed at addressing the
issue of gene independent effects due to copy number amplification. CRISPRCleanR
uses an unsupervised approach to segment single sgRNA foldchange across the
genome, without requiring prior knowledge of the copy number of the targeted loci. This
method outputs sgRNA fold changes and normalized read counts, making it compatible
with other analysis tools for downstream hit discovery.
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3.2.4: JACKS
To address the issue of alternate sgRNAs targeting the same gene confounding
the essentiality estimates obtained from CRISPR screening, researchers at the Sanger
institute developed JACKS (Joint Analysis of CRISPR/Cas9 Knock-out Screens)74. This
is a Bayesian method that models efficacies of all sgRNAs across multiple screens using
the same library. JACKS models the log2 foldchange of sgRNAs comparing treatment to
control (or an endpoint screen compared to a reference). The authors report that the
JACKS method provides improvements on gene essentiality estimations, and ultimately
allow for the scaling down of library sizes in terms of the number of sgRNAs per gene.
3.2.5: BAGEL
BAGEL (Bayesian Analysis of Gene EssentiaLity)75 is, as the name suggests, a
Bayesian method that relies on a set of gold standard genes – “core essential” genes that
are considered essential in all cell lines and contexts, and a set of “non-essential” genes
that do not induce drop-out when knocked out in any cell lines or contexts. These gold
standard genes were initially curated from previously published data describing essential
and non-essential genes. This list was further expanded with increasing availability of
CRISPR screens, with the final list containing 684 core essential genes and 927 nonessential genes69. The fold-change in the guide RNA (sgRNA) abundance after knockout
of each gene is measured, and compared against the fold change distribution of the core
essential and the non-essential reference sets. BAGEL then computes a ratio, the Bayes
Factor (BF), which is the log2 likelihood of each gene belonging to either the core
essential gene distribution or non-essential gene distribution. An updated version of the
BAGEL, platform, BAGEL version 276, was recently released which provides better quality
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control and improved dynamic range of the BF, allowing for better inferences of the
magnitude of essentiality.
3.3: Introduction of Surfaceome Library and Logic
Application of a perturbation-based functional genomics approaches, while
incredibly informative in comprehensively characterizing the network of deregulated
cellular signaling, is currently not feasible directly in tumor samples. Current genome-wide
approaches in traditional cell lines, while optimized, may not be a faithful recapitulation of
the diversity of signaling of the disease they represent. Especially in the case of cancer,
cell lines may not maintain the level of heterogeneity of the original patient tumor, and
tend to become more homogenous with further passaging77. Patient-Derived Xenografts
(PDXs), which are direct implants of patient tumors into murine models, along with
associated PDX-derived early passage cell lines (PDX lines) address some of the
shortcomings of using traditional cancer cell lines by better maintaining morphological,
genetic and molecular characteristics of the original tumor78. Leveraging this unique
strength of PDX’s in more closely recapitulating the dynamics of patient tumors, we aim
to establish a functional genomics approach to more comprehensively characterize the
specific dependencies within the context of each PDAC model.
Genome-wide CRISPR library screens are demonstrated to be a feasible and
easily accessible method to quantify model specific vulnerabilities in traditional cells lines
and in vitro settings of pre-selected screen-able models. However, this remains
challenging in alternatives such as patient derived xenografts (PDX’s), in vivo models or
clinical samples. The large number of transduced cells required for adequate coverage
may not be feasible in models with slow doubling time or in vivo implantation. CRISPR
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screens have been conducted in human cancer cell lines on a whole-genome basis at a
coverage of 200-300x, which translates to 14 to 16 million transfected cells. While this is
feasible when conducting in vitro screens, it is not feasible to perform screen -in vivo while
maintaining the complexity of the library. For this reason, custom, small library CRISPR
screens asking a targeted question centering around a hypothesis are becoming more
common79,80.
To more closely recapitulate the signaling diversity of PDAC patient tumors, the
Draetta lab, led by Dr. Wantong Yao, Dr. Johnathon Rose and Dr. Alessandro Carugo
have optimized a screening protocol for parallel in vitro and in vivo CRISPR screening in
PDX models81,82. Owing to the limitations of conducting genome wide screens in this
setting, we have developed a custom PDAC prioritized screening library, termed the
“surfaceome” library. This library was initially developed as an RNAi library with an
emphasis on targeting proteins localized and integrated into the extracellecular face of
the plasma membrane82. Surface protein targets were included in the library based on
evidence of differential expression in pancreatic tumors compared to matched-normal
tissue, copy number versus RNA expression correlation trends from the TCGA PDAC
dataset, and SILAC screening for mutant Kras dependency. Upon completion of the
parallel in vitro and in vivo RNAi screens, we subsequently built a custom sgRNA library
that expanded upon the RNAi-identified protein surface dependencies across all tested
models. Using a CRISPR-based approach, the library incorporated sgRNAs targeting
highly connected proteins defined by a stringent STRING protein-protein interaction (PPI)
network used to evaluate oncogenic signaling redundancies and interpret codependencies. The final iteration of the surfaceome library is a PDAC prioritized surface
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protein library including the downstream targets totaling 657 genes, with 5 sgRNA each,
of which 50 “core” essential and 50 non-essential genes were selected from the Hart
reference set. This library was jointly designed by Dr. Wantong Yao, Dr. Johnathon Rose,
Dr. Alessandro Carugo and Sahil Seth.
3.4: Analysis of Custom Library Screens
Parallel in vitro and in vivo CRISPR screens were performed by Dr. Johnathon
Rose on three PDX lines (PATC69, PATC124 and PATC53) (See methods). We
conducted each in vitro CRISPR screen as a time course with a reference time-point and
three follow up time-points, with a matched in vivo endpoint. Current analytical
frameworks described above, such as MaGeCK, CERES, JACKS, and BAGEL are
designed for genome-wide screens, and are not tailored to account for the far smaller
training sets of these screens.
Thus, in addition to developing a sophisticated experimental framework to conduct
custom library CRISPR screening, we have also developed an analytical framework to
better model smaller datasets. Here, we introduce an adapted algorithm of the BAGEL
method implemented as an option within the software, Low-Fat BAGEL for the analysis
of small, targeted library CRIPSR screens. We demonstrate the utility and improved
accuracy of Low-Fat BAGEL compared to other genome-wide analysis tools
benchmarked in our custom library CRISPR screens of two pancreatic cancer PDX
derived cell lines.
3.5: Surfaceome Library Analysis using BAGEL v1
The surfaceome library contains PDAC prioritized surface proteins and
downstream targets totaling 657 genes, with 5 sgRNA each, of which 50 core essential
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and 50 non-essential genes were selected from the Hart reference set. With the inclusion
of the Hart reference set, we first analyzed our screens using the BAGEL algorithm.
In the original BAGEL algorithm75, the Bayes Factor of a given guide is computed
as a log2 likelihood of being essential based on comparison to the foldchange
distributions of the core essential and non-essential genes. Gene level Bayes Factors are
obtained by summing across all guides corresponding to that gene. On a genome-wide
scale, relying on our gold standard set of five guide 684 core and 927 nonessential genes,
respectively, 1611 genes are bootstrapped 1000 times, and a mean BF per guide is
calculated. As previously mentioned, version 1 of BAGEL also implemented a limited
minimum and maximum kernel density estimate of log2 foldchange for calculating BF to
decrease the impact of outliers.
Initial analysis of our custom library screens with 50 core essential and 50
nonessential genes, using version 1 of BAGEL yielded irregular results despite good
separation of essential and non-essential genes. As an example, the results from Day 12
of PATC69 are shown below. In this screen, there was good separation of the core
essential and non-essential gene distribution (Figure 1). Despite the early time-point, Day
12, the core essential genes demonstrate a clear negative foldchange, while the nonessential genes show a distribution centered at or around 0. Of note in the screen is an
outlier in the non-essential distribution, indicated by the arrow in Figure 1.
The impact of this single outlier gene present in the nonessential gene set
adversely affects the precision-recall of the BF in a PATC69 screen at Day 12 (Figure 1).
The Bayes Factor distributions of these genes is demonstrated in Figure 2, where the
same outlier gene in the nonessential set outperforms every other gene, despite most of
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the essential genes having a lower log2 foldchange. This is an instance of the impact of
the upper and lower bounds on the Bayes Factor distributions of another PATC69 screen
after on Day 12 despite clear separation of core-essentials and non-essentials is
demonstrated in Figure 1. This highlights the need for analysis strategies more suitable
for correctly modeling and fitting custom library datasets.
To address this, we developed Low-Fat BAGEL, an adapted framework of the
updated BAGEL algorithm to more accurately analyze small screens with limited training
sets. In Low-Fat BAGEL, all of the analysis is focused on each sgRNA as an independent
data point rather than on gene level. Only 100 permutations are performed on the
individual guides of the reference set, rather than on the level of each gene. In the case
of our PATC69 and PATC124 screens, 500 core-essential and nonessential guides are
bootstrapped across 100 permutations, and the resulting BF for each guide computed is
an average of all permutations. An aggregate BF for each gene is then obtained by
summing the BFs of individual guides. Log2 fold-change was calculated on a guide level
by comparing each time point to the reference time point for each model. Screen quality
and efficient drop out was assessed by comparing the log density ratio log2 foldchange
of core essential versus non-essential guides.
The BAGEL and BAGELv2 calculate a Bayes Factor (BF) as a log likelihood of
gene essentiality trained on gold-standard core essential and non-essential genes75,76.

𝐵𝐹 =

Pr(𝐷 | 𝑒𝑠𝑠𝑒𝑛𝑡𝑖𝑎𝑙)
∫ Pr(𝐷 |𝑘, 𝑒𝑠𝑠𝑒𝑛𝑡𝑖𝑎𝑙) Pr(𝑘 | 𝑒𝑠𝑠𝑒𝑛𝑡𝑖𝑎𝑙) 𝑑𝑘
=
Pr(𝐷 | 𝑛𝑜𝑛𝑒𝑠𝑠𝑒𝑛𝑡𝑖𝑎𝑙)
∫ Pr(𝐷 |𝑘, 𝑛𝑜𝑛𝑒𝑠𝑠𝑒𝑛𝑡𝑖𝑎𝑙) Pr(𝑘 | 𝑛𝑜𝑛𝑒𝑠𝑠𝑒𝑛𝑡𝑖𝑎𝑙) 𝑑𝑘
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In Low-Fat BAGEL, a random bootstrap of core essential and non-essential guides
is used as the training set to generate log density curves of the essential and nonessential fold-change distribution. This distribution is used to generate a linear regression
model (k) of the fold-change to control for the influence of outliers. The linear interpolation
method replaces the maximum and minimum kde for the essential and non-essential
distribution implemented in BAGEL v1. This linear interpolation model is also
implemented in BAGEL v2.
Over 100 permutations of the training set, Low-Fat BAGEL calculates the BF of all
guides in the library, by comparing the log2 fold-change of each guide (D) to the
distribution of fold-changes of the essential and non-essential genes. The final BF of each
individual guide is computed as the mean across 100 iterations, and a gene level BF was
calculated as the sum of all guides for that gene. The impact of using Low-Fat BAGEL on
the same screen (PATC69, Day 12) is demonstrated in Figure 3. Precision-Recall curves
are a good measure of the success of prediction of classes. Precision, also called positive
predictive value, is the fraction of the number of true positives over all the positive
predictions. In this case, precision is the proportion of total core essential genes over the
sum of both core and non-essential genes predicted to be essential. Recall, also known
as sensitivity, is the proportion of positives that were correctly identified over the total
population of true positives (true positives + false negatives). In the case of our screens,
recall would be the total number of core essential genes correctly predicted to be essential
over the total number of core essential genes in our library. The precision-recall curve
provides a dynamic view of how these values change with varying cut offs of the BF to
deem essentiality. The R package ‘ROCR’ was used to generate Precision-Recall curves
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of the essential and non-essential gene level BF83. When we compare the PrecisionRecall curves for PATC69, Day 12 between BAGELv1 and Low-Fat BAGEL, we are able
to visually appreciate the improvement in performance and accuracy in modeling the
smaller dataset and controlling for outliers (Figure 4).
With the final optimized Low-Fat BAGEL, we also compared its performance
against JACKS, CERES and MaGeCK. This comparison was made with data from two of
our models – PATC69 and PATC124, across all our time points. Each time-point
contained three replicates, which were regarded individually to compare methods. To
reduce the Precision-Recall curve to a single metric, we computed the F measure of the
screen. The F measure is a harmonic mean of precision and recall. The nature of the
precision-recall curve is a trade-off – as the precision of the screen nears a value of 1,
recall will near a value of 0, and vice versa. Given this, the F measure, which identifies
an optimal balance between precision and recall provides a value between 0 and 1, with
higher values representing higher screen quality. Comparison to other genome-wide
analytical methods, Low-Fat BAGEL analyses demonstrate better performance and a
more accurate classification of essential and nonessential genes in our screens (Figure
5).
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Figure 1: Distribution of the essential and non-essential gene set of the
surfaceome library in PATC69, Day 12.
Kernel density estimate plots comparing the log2 fold-change distribution of all essential
and non-essential guides (n=285, n=280 respectively) for PATC69 in vitro Day 12 screen
demonstrating the differences in dropout between the two distributions. The arrow
indicates the outlier guides in the non-essential distribution that demonstrate dropout in
this context.

37

Figure 2: Bayes Factors of the core essential and non-essential genes in the
PATC69 Day 12 screen derived from BAGEL v1.
Gene-wise BFs of essential and non-essential genes only from PATC69 in vitro Day 12
screen calculated from BAGEL v1 designed for genome-wide CRISPR screens. Genewise BF is calculated as a sum of guide level BFs. The dotted line indicates a BF cutoff
of 0. BFs above this value indicate that a gene is more likely to be essential than nonessential. The box highlights an outlier gene in the non-essential distribution (marked by
the arrow in Figure 1) that scores higher than the true essential genes.

38

Figure 3: Bayes Factors of the core essential and non-essential genes in the
PATC69 Day 12 screen derived from Low-Fat BAGEL.
Gene-wise Bayes Factors of essential and non-essential genes PATC69 in vitro Day 12
screen calculated from Low-fat BAGEL designed for custom library CRISPR screens.
Gene-wise BF is calculated as a sum of guide-level BFs. The dotted line indicates a BF
cutoff of 0. BFs above this value indicate that a gene is more likely to be essential than
non-essential.
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Figure 4: Precision-Recall curves comparing the performance of BAGEL v1 and
Low-Fat BAGEL.
Precision-Recall curves of BFs of essential and non-essential genes from the PATC69 in
vitro Day 12 screen comparing the performance of BAGEL v1 and Low-fat BAGEL. These
curves were derived from the BFs computed in Figure 2 and Figure 3.
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Figure 5: Comparison of F measures of known genome-wide CRISPR screen
analytical methods to Low-Fat BAGEL across PATC69 and PATC124 in vitro and
in vivo screens.
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3.6: Low-Fat BAGEL in Surfaceome Screens
With the optimized method in Low-Fat BAGEL, we established an analytical
protocol for our surfaceome screens. As mentioned, we used three available PDX lines
(PATC69, PATC124 and PATC53) that were compatible with the CRISPR-based
screening technology in vivo. We conducted each in vitro CRISPR screen as a time
course, with three in vitro time-points and with a matched in vivo time-point matching the
last in vitro time-point. Each time-point had three replicates each. The Day 0 Reference
time-point had two replicates each. BFs were calculated for each replicate compared to
the Reference time-point for each respective model. Results from the latest in vitro timepoint, Day 30 and the in vivo time-point were considered to identify essential genes.
Figures 6-8 illustrate the screen quality with the separation of core essential and nonessential genes across all replicates and time-points for PATC69, PATC124 and
PATC53, along with the corresponding BFs of each screen per time-point calculated as
the mean of all replicates.
In order to be able to compare the BFs across all our screens, we quantile
normalized our BFs across the entire cohort. Quantile-normalized BFs (BF > 1) were
utilized as our threshold for determining essential genes represented in the three models
in vitro and in vivo. Dependencies among the three PDX lines, in both in vitro and in vivo
conditions, were highly diverse, with little overlap. This is presented in Figure 9.
Ribosome-associated RACK1, RPL30, and the MYC proto-oncogene were the only
shared vulnerabilities identified in all in vivo and in vitro screening contexts. Figures 1012 illustrate the diversity of the surfaceome genes that are essential in vivo in each
context. For visualization, we are presenting a STRING PPI of the surfaceome genes that
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showed essentiality in at least one model, with genes in red being essential in each model,
and genes in blue not showing essentiality in that context. We integrated quantilenormalized BFs with the STRING PPI network used to build the sgRNA library and
generated dependency networks for each model. Dependency networks were merged
across all three PDX lines based on overlapping essentiality thresholds (BF >1) for in vivo
and in vitro contexts.
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Figure 6: Paired density plots and Bayes Factor estimates for PATC69.
(Right) Density plots of each time-point and replicate of PATC69. Log2 foldchange is
calculated from the Day 0 reference time-point. The injection point time-point represents
the population of cells that was implanted in vivo, at a point before we see separation of
essential and non-essential guides. Density plots in blue represent the non-essential
genes in the surfaceome library that have a distribution centered at or around 0. Density
plots in red represent the essential genes in the surfaceome library, which have an
increasingly negative log2 foldchange distribution in later time-points.
(left) BF plots of each time-point averaged across replicates of PATC69. BF plots in blue
represent the non-essential genes in the surfaceome library that have a tightly distributed
and highly negative BF. BF plots in red represent the essential genes in the surfaceome
library, which have a distribution with highly positive BFs, indicating increasing confidence
in essentiality.
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Figure 7: Paired density plots and Bayes Factor estimates for PATC124.
(Right) Density plots of each time-point and replicate of PATC124. Log2 foldchange is
calculated from the Day 0 reference time-point. The injection point time-point represents
the population of cells that was implanted in vivo, at a point before we see separation of
essential and non-essential guides. Density plots in blue represent the non-essential
genes in the surfaceome library that have a distribution centered at or around 0. Density
plots in red represent the essential genes in the surfaceome library, which a show a slight
negative log2 foldchange distribution, but overlap with the non-essential distribution.
(left) BF plots of each time-point averaged across replicates of PATC124. BF plots in blue
represent the non-essential genes in the surfaceome library that have a moderately
negative BF. BF plots in red represent the essential genes in the surfaceome library,
which have a distribution with positive BFs, and clear separation from the non-essential
distribution, indicating accuracy in identifying essentiality.
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Figure 8: Paired density plots and Bayes Factor estimates for PATC53.
(Right) Density plots of each time-point and replicate of PATC53. Log2 foldchange is
calculated from the Day 0 reference time-point. The injection point time-point represents
the population of cells that was implanted in vivo, at a point before we see separation of
essential and non-essential guides. Density plots in blue represent the non-essential
genes in the surfaceome library that have a distribution centered at or around 0. Density
plots in red represent the essential genes in the surfaceome library, which a show a slight
negative log2 foldchange distribution, but overlap with the non-essential distribution.
(left) BF plots of each time-point averaged across replicates of PATC53. BF plots in blue
represent the non-essential genes in the surfaceome library that have a moderately
negative BF. BF plots in red represent the essential genes in the surfaceome library,
which have a distribution with positive BFs, and clear separation from the non-essential
distribution, indicating accuracy in identifying essentiality.
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Figure 9: Comparing essential genes across models in vitro (top) and in vivo
(bottom).
(top) Venn diagram of functional targets derived from in vitro, orthotopically implanted,
CRISPR screening of PDX lines using a quantile-normalized BF > 1, with six total genes
showing in vitro essentiality across all three models.
(bottom) Venn diagram of functional targets derived from in vivo, orthotopically implanted,
CRISPR screening of PDX lines using a quantile-normalized BF > 1, with eight total genes
showing in vivo essentiality across all three models.
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Figure 10: CRISPR screening results from PATC69.
In vivo CRISPR screening results from PATC69 overlaid onto a merged STRING PPI
force-directed diagram. The BF of each gene indicates the degree of vulnerability of the
gene, with BF > 1 indicating an essential gene.
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Figure 11: CRISPR screening results from PATC124.
In vivo CRISPR screening results from PATC124 overlaid onto a merged STRING PPI
force-directed diagram. The BF of each gene indicates the degree of vulnerability of the
gene, with BF > 1 indicating an essential gene.
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Figure 12: CRISPR screening results from PATC53.
In vivo CRISPR screening results from PATC53 overlaid onto a merged STRING PPI
force-directed diagram. The BF of each gene indicates the degree of vulnerability of the
gene, with BF > 1 indicating an essential gene.
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3.7: Discussion
Here, we applied a custom functional genomics approach for screening PDAC
PDX lines in parallel in vivo and in vitro screens. We designed small, customized CRISPR
libraries were used to ensure maintenance of library complexity in vivo, Data from these
sgRNA screens was not amenable to analysis using current analytical frameworks, which
are designed for genome-wide screens and are not tailored for the small training sets of
our custom library. To address this, we adapted the BAGEL framework to create Low-Fat
BAGEL. We demonstrated that Low-Fat vastly improves the ability to identify essential
genes in the context of our PDX models.
With the advent of CRISPR screening technology to answer more and more
targeted and nuanced biological questions, the popularity of targeted CRISPR libraries
continues to grow. As experimental methodologies and protocols enable more in-depth
in vivo modeling, as well as other platforms such as T-cell screening, organoids, etc.,
having an equally robust analytical platform is equally important. Low-Fat BAGEL is able
to address this need. Currently, we have released Low-Fat BAGEL as a stand-alone
Python based tool, and is also available as an option for “small library screens” within the
BAGEL v2 platform.
Using Low-Fat BAGEL, we can the minimum threshold for the number of core
essential and non-essential genes required to accurately calculate the likelihood of a
given gene being essential. For instance, using the large number of publicly available
genome-wide screens of varying quality, we can down-sample the number of control
genes needed in a library to recapitulate genome-wide results, allowing for further
optimization of targeted libraries.
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Chapter 4: Quantifying PDAC Diversity with Biological Networks

This work is based on efforts outlined in our recent BioRxiv submission “Diversity
Across the Pancreatic Ductal Adenocarcinoma Disease Spectrum Revealed by
Network-Anchored Functional Genomics” by Rose and Srinivasan, et al. (2020), DOI:
https://doi.org/10.1101/2020.09.17.302034. As co-first author, Dr. Johnathon Rose
provided substantial experimental support for this effort, enabling our findings. The
manuscript is currently under review.
4.1: Patient Derived Xenograft Models
PDAC is a disease characterized by its dense desmoplastic stroma and genetic
alterations that lead to disease development and progression. Owing to this, researchers
are focusing on ways to model the tumor beyond using traditional cell lines to better
capture and recreate the complex factors involved in tumor development and progression.
Transgenic mouse models, notably KRAS mutant genetically engineered mouse models,
serve as good model systems to study PDAC disease development and treatment
response84. However, studying the complex cascade of genetic alterations beyond that of
KRAS, remains challenging in this setting. One strategy to study late stage and metastatic
PDAC tumors is to directly implant a patient tumor sample into an immune-deficient
mouse, or Patient Derived Xenografts (PDXs)85. Both directly and indirectly implanted
PDX’s

utilize

clinical

patient

samples

retain

signaling

resulting

from

tumor/microenvironmental interaction, are capable of developing metastases, and at least
partially recapitulate the heterogeneity evidenced in patients. An additional benefit of
PDXs is the ability to delineate molecular signaling innately derived from human tumor
cells, vs. the murine stromal component (as reviewed by Garcia, et al)86.
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In collaboration with Dr. Michael Kim and Dr. Scott Lowe, the IACS/TRACTION
group has established a growing list of PDAC PDX tumors that have been extensively
characterized for use in preclinical drug testing44. To assess the diversity of transcriptomic
signatures among PDAC tumors, we utilized 48 of these early passage patient-derived
PDAC xenografts, which maintain the cellular heterogeneity of tumor lesions while
reducing the contribution of the stromal components prevalent in these tumors44,85.
Clinical data corresponding to the patients these PDXs were derived from53 are presented
in Table 1.
We performed RNA sequencing and whole exome sequencing (WES) on the 48
PDX models. First, we sought to quantify our models along previously reported
heterogeneity within PDAC. The “oncoplot” feature within the R package maftools87 was
utilized to visualize the mutational spectrum across the genes identified as relevantly
mutated by the PDAC TCGA paper12. We found that the general mutational spectrum of
our tumors matches the frequency of mutations previously described (Figure 13). In our
cohort, 93% of models harbored a KRAS mutation, followed by 84% of patients with TP53
mutations, and 27% of patients with CDKN2A and SMAD4 mutations each. Interestingly,
we found a higher than previously reported mutation rate in ARID1A (31%), ATM (29%)
and GNAS (29%).
As previously described, there are currently several subtyping methodologies
described within PDAC, with the general consensus of the field agreeing on two broader
subtypes “Classical” and “Basal-like”40. This two-subtype classification was described by
Moffitt et al using computationally micro-dissected patient and PDX models. The Moffitt
classification method is based on a set of 21 classical subtype genes and 25 basal-like
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genes. We assigned the Moffitt classification of classical or basal to our 48 PDX models
using log normalized and scaled counts of 21 classical and 25 basal genes for PDX PDAC
model classification described by consensus clustering into two groups using the R
package ConsensusClusterPlus88. The clusters were manually assigned as classical and
basal based on high expression of each group of genes. The breakdown of classical and
basal-like models within our cohort is presented in Figure 14. We captured a level of
transcriptional diversity consistent with the previously defined Moffitt classification status
and distribution of classical and basal-like pancreatic adenocarcinoma. Within the tumors
categorized as classical and basal-like, only a small proportion of tumors exclusively
express markers that are either classical or basal-like. The heatmap in Figure 14 shows
that a sizable portion of tumors express some of the marker genes from the other subtype,
or low expression of markers from both subtypes. Consensus clustering requires the user
to specify the number of clusters, and in this case, assigning them as classical or basallike binarizes tumors even though these subtypes might biologically present as a
spectrum rather than a category. This “spectrum” is partially addressed with the more
recent Toronto classification, that identifies a “hybrid” group that expresses both classical
and basal-like genes, but is still a categorical classification42.
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Table 1: Clinical features of patients corresponding to the PDAC PDX models
used in this study
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Figure 13: Mutational diversity of the PDAC PDX models included in this study.
Oncoplot of common PDAC-associated mutations in the 48-model PDX cohort displays
mutation frequencies similar to previous publications.
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4.2: Utility of Co-expression Analysis in Large Datasets
Our aim in this section was to develop a comprehensive approach to quantify and
transcriptional diversity arising from PDAC tumor cells. Methods such as differential gene
expression face the disadvantage of requiring a comparison group, typically normal
tissue, which is not easily obtained in large numbers. In addition, differential expression
analysis identifies genes with concordantly dysregulated signaling between two groups,
making interrogation of heterogeneity between models challenging. Comparing tumors
vs normal samples would capture the general transcriptional differences defining PDAC,
while comparing tumor models or conditions to each other would highlight nuanced
changes between the two. However, neither of these methods would capture the intrinsic
diversity across a large cohort of PDAC tumors.
An alternative to these approaches, is co-expression analysis to capture the
transcriptional diversity of a cohort of models. Co-expression analysis can be a powerful
tool to explore candidate genes within the context of the entire genome, and also
characterize and interrogate specific biological processes and functions. Specifically,
constructing a co-expression network is a powerful integration of large transcriptomic
datasets89-92. Characterization of modules, or groups of genes that are co-expressed
across a large cohort. This can serve as a platform for evaluating specific biological
functions, mine for future hypothesis, contextualize “your favorite gene” within the
behavior of a large network of genes, and predict the function of genes with previously
unknown functions, to name a few.
Global pairwise co-expression networks that are constructed as undirected
networks, while computationally intensive, provide a comprehensive view of
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transcriptional heterogeneity93,94. Undirected global networks are based on pairwise
relationships between all genes in a cohort, pruned based on a determined threshold for
inclusion. Identification of highly connected genes into clusters that are further annotated
can aid in the characterization of biological functions. Interconnectivity within each cluster
can inform on the core module of genes that might be implicated in regulating a specific
biological function, whereas high connectivity outside a cluster can inform on higher order
relationships between different biological functions. The basic organization of a network
consists of a node – individual units of information, in this case, a gene. These nodes are
connected to each other with edges or links, which in this case, would be a co-efficient of
co-expression. These nodes and edges together form a network, or a graph94.
To associate genetic drivers with clinically predictive transcriptomic signatures, we
developed a dedicated PDAC co-expression network that we derived from our curated
cohort of 48 PDXs. Co-expression of a set of genes is indicative of genes controlled by
the same regulatory program, belong to the same signaling pathway or have similar
functions92,93. By developing a comprehensive genome-wide co-expression network, we
are able to identify large sets of genes that are co-regulated across a large set of PDAC
models.
4.3: Construction of the PDAC Co-Expression Network
To identify patterns of co-expression between genes across our cohort, we first
selected genes with dynamic expression. Genes with stable high or low expression
across all models would not be informative to study trends of co-expression. With our
cohort of 48 models, we retained 17168 genes with raw read counts in at least 80% of all
samples. Following this, we computed gene-wise median absolute deviation across
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samples from the normalized read counts. Median absolute deviation provides a measure
of dispersion of the data that is more robust to outliers than measures such as standard
deviation. With median absolute deviation, 8505 genes exceeding the 40th percentile were
filtered to consider highly variable genes. Spearman correlations were calculated as a
metric of pairwise gene co-expression across the 8505 highly variable genes. Spearman’s
rank correlation provides a nonparametric measure to assess the linear relationship
between two variables. Spearman’s rho provides a more conservative estimate without
assuming the normality of the distribution of every one of the 8000+ genes being
considered. This gave over 72 million pairwise correlations. In order to prune our network,
and do so while maximizing the likelihood of retaining interpretable gene-pairs, we limited
our dataset to positively correlated gene pairs. Using an adjusted p value of 0.05, 366,836
correlations passed this threshold.
In order to prune the network to prioritize biologically relevant gene pairs, a
Bayesian framework developed by Yang, et al, Log Likelihood Score (LLS), was applied95.
This paper curated a “positive gold standard” list of biologically relevant gene pairs and
“negative gold standard” gene pairs with no known functional annotations. As with a
standard Bayesian formula, the LLS is a likelihood ratio of how likely any given Spearman
rho value between two genes is likely to represent biological relevance over the rho value
representing no biological relevance. This is calculated using the distribution of spearman
correlations of gene pairs from the positive gold standard set and the correlations of gene
pairs from the negative gold standard as posterior probabilities. The resulting score is the
likelihood of any given gene pair belonging to the biologically relevant group, with positive
score indicating higher likelihood of biological relevance, with higher scores indicating
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higher confidence. COEXPEDIA, a co-expression database employing the LLS method
to prune edges, uses an LLS score of 1 to identify gene pairs of high predicted biological
relevance. Here, we used an extremely stringent cut-off of a log likelihood score of 2.5 to
identify gene pairs to be included in the network. This resulted in the PDAC co-expression
network with a total 103,000 correlations of 7,828 genes, of which all but 75 genes had
an adjusted p value less than 0.05.
4.4: Clustering and GO Annotation of the PDAC Co-Expression Network
Our next step was to identify clusters of co-expressed genes within the PDAC CoExpression Network. For this, we utilized a tool called InfoMap96. It incorporates
MapEquation96, a community detection algorithm for large networks, which was used to
cluster the network. All gene pairs were inputted into Infomap, and three hierarchical tiers
of clusters were produced. In order to assign clusters, if the third tier contained more than
50 genes, it was assigned to an individual cluster. In the event that the third tier contained
less than 50 genes, it was folded into the second tier, all of which formed a cluster. This
was the case with cluster 29-31, which are larger encompassing clusters. This resulted
in a total of 31 clusters, which were further genome ontology (GO) annotated97. For the
resulting 31 clusters, the R package GOseq98 was used to conduct hyper-enrichment
analysis of Gene Ontology Biological Processes pathways on each cluster. The R
package “revigo”99 was used to prioritize and visualize GO pathways to represent their
hierarchical class. The resulting PDAC co-expression network is presented in Figure 15
along with its GO annotated pathways. Revigo annotated pathway labels are presented
in Figure 16.
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We measured PDAC diversity by applying a dimensional reduction approach on
our 31 defined clusters. Specifically, we quantified the mean expression of each cluster,
or centroid score, on a tumor-by-tumor basis, for all 48 PDX models in the PDAC cohort.
To generate a cluster level enrichment score, we calculated a centroid score per cluster
by taking the mean log-normalized expression of all genes in each cluster for each
sample. A comprehensive overview of the 31 centroid scores across the PDX models
was generated using the R package ComplexHeatmap100.
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Figure 15: Network hairball of the PDAC Co-expression network.
Force-directed layout of the PCEN. Gene clusters, defined by Gene Ontology (GO),
visually highlight nodes with a minimum of 12 edges.
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Figure 16: Treemaps of Cluster by Cluster GO Annotations within the PDAC Coexpression Network.
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Figure 17: Cluster centroids derived from the PDAC co-expression network and
the associated correlations between clusters.
(Top) Heatmap depicting the cluster centroid scores of each of the 31 clusters across the
48 PDX models. The centroid is computed as the mean normalized expression of all
genes per cluster. The column annotation above presents the Moffitt classification of the
PDX models, with the blue annotation corresponding to classical models and orange
annotation corresponding to basal models.
(Bottom) Heat map depicting Pearson positive (red) and negative (blue) correlations
between cluster centroid scores across 48 PDX models. Starred correlations represent
an adjusted P value < 0.05.
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4.5: Associated Mutations with Cluster Enrichment
To determine if the mutational background of a model was significantly associated
with cluster enrichment across the PDX cohort, we applied UNCOVER101, a method to
identify complementary patterns of mutation enrichment across groups using a filtered
set of “high impact” mutations and the cluster enrichment centroid scores per model. The
filtered set of mutations was generated by identifying canonical mutations with gnomAD102
allele frequency less than 1%, “moderate” and “high” impact, and limited to nonintronic/non-coding and synonymous mutations. Interestingly, we identified a limited
cluster-mutation association between ACVR2A, RREB1, and MARK2 mutations and
tumors with significant enrichment in Cluster 21 (Table 2). PDAC-associated loss-offunction mutations in RREB1, which encodes a zinc finger transcription factor that binds
to RAS-responsive elements, have been reported in the TCGA PDAC cohort. RREB1 is
a positive regulator of the zinc transporter, ZIP3, with loss-of-function playing a potential
role in limiting zinc uptake and shielding developing tumors from the cytotoxic effects of
high cellular zinc concentrations103. RREB1 has also been described as a KRASregulated SMAD co-factor involved in driving the expression of epithelial-to-mesenchymal
(EMT) transcription factors104. While the significance of mutations in the serine-threonine
kinases, MARK2 and ACVR2A, is relatively poorly understood in PDAC, dysregulation in
these genes could implicate the regulation of epithelial polarity and downstream SMADassociated signaling, respectively105-107. Associating co-expressed and annotated gene
clusters with these less frequent mutations in PDAC could aid in illuminating the molecular
signaling, and potential therapeutic avenues, underlying these genomic alterations
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Table 2: Results from the UNCOVER analysis reveal complementary gene
mutations associated with cluster centroid-based enrichment
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4.6: Prominent Anticorrelated Cluster Signatures
We observed general patterns of anti-correlative clusters across the PDAC PDX
cohort that were reflected in cluster positioning and subsequent cross-cluster
connectivity. The most significant anticorrelated signatures were identified in clusters
predominantly localized to adjacent ends of the force-directed layout (Figure 15), and the
non-overlap of these adjacent anti-correlated cluster trends implicates multiple distinct
molecular signaling contexts that represent the immense diversity across the PDAC
disease spectrum. The top anti-correlative signatures were quantified between two
opposing clusters: Cluster 1 vs. Cluster 23, respectively enriched for lipid metabolism vs.
cell development; and Cluster 2 vs. Cluster 13, respectively enriched for Golgi-vesicle
transport vs. nuclear-transcribed mRNA catabolism (Figure 18). Additionally, the PDAC
co-expression network also highlighted GO annotated clusters critical for proliferating
tumor cells; specifically, Cluster 15, cell cycle, and Cluster 16, mitochondrial transport and
organization (Figure 18). These findings reveal that, along with 31 unique gene clusters,
two distinct anti-correlated cluster signatures contribute to PDAC tumor diversity and have
the potential to provide context for tumor cell-intrinsic vulnerabilities.
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Figure 18: Anticorrelations of clusters in the PDAC co-expression network with
the corresponding GO annotations.
(Top) Force-directed layout of the PCEN (top) and matching GO hierarchical treemaps
(bottom) of prominent anti-correlative cluster centroid trends across the PDAC coexpression network highlighting Cluster 1 (Lipid metabolism) vs. Cluster 23 (Cell
development).
(Bottom) Force-directed layout of the PCEN (top) and matching GO hierarchical treemaps
(bottom) of prominent anti-correlative cluster centroid trends across PDAC co-expression
network highlighting Cluster 2 (Golgi vesicle transport) vs. Cluster 13 (mRNA catabolism).
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4.7: Cluster 1 and 23 Anticorrelation Recapitulates Moffitt Signatures
Upon observing the strong anti-correlative trend between Cluster 23 and Cluster
1, we evaluated the Cluster 1 centroid scores among the entire PDAC PDX cohort (Figure
19). Interestingly, Cluster 1 unbiasedly localized the entire set of 21 classical signature
genes from the Moffitt classification. The Cluster 1 centroid scores across our PDX cohort
showed low variance among Moffitt-defined classical models40, but a wider range and
significant depletion of Cluster 1 gene expression (p = 3.67 x 10-6) was observed in basallike models (Figure 19). Visualized another way, we paired the centroid scores of Cluster
1 and Cluster 23 (C1vC23) and identified a near perfect anticorrelation between the two
clusters across the PDX cohort. Integrating the Moffitt classifications with the C1vC23
enrichment anticorrelation demonstrates that models enriched in C1 and depleted in C23
are all classical, and conversely, models enriched in C23 and depleted in C1 are all basallike. There is a sizable group of models with partial enrichment of both C1 and C23, that
are equally assigned to either classical or basal-like groups. This is a similar trend
previously observed with the Moffitt classification genes itself, with a proportion of
samples showing partial enrichment of both classical and basal-like marker genes40.
Taken together, these trends suggest that the classical and basal-like subtypes of PDAC
are two ends of a continuum, rather than two discrete groups. This suggests the existence
of a transitionary state of tumors that harbor both classical and basal-like phenotypes.
Indeed, by applying K means clustering on only the Cluster 1 and Cluster 23
centroid scores, we separated the PDX cohort into three groups108,109 (Figure 20): 1)
enrichment in Cluster 1 represented Moffitt-defined classical models, 2) enrichment in
Cluster 23 represented Moffitt-defined basal-like models, and 3) models with partial
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enrichment of both Clusters 1 and 23 (Figures 21), which we termed “quasi-basal”. Thus,
our C1vC23 signature provides a continuous transcriptomic signature that expands on
the original binary Moffitt classification and uncovers a transitionary quasi-basal
phenotype of PDAC with molecular signatures falling along a continuum.
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Figure 19: Module centroid scores of Cluster 1 between Moffitt defined classical
and basal models.
Violin plot of average Cluster 1 centroid score across Moffitt-defined classical and basallike models. Box-whisker plots show median ± first and third quartiles. P values are
derived from t–test (n = 48 PDX tumors).
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Figure 20: K means clustering reveals optimal k=3 using the Cluster 1 and Cluster
23 centroid scores across the PDX models.
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Figure 21: Prominent anti-correlated clusters recapitulate a granular spectrum of
“classical”, “quasi-basal”, and “basal-like” models that are associated with
clinical features.
(Right) K means clustering reveals optimal k=3 using the cluster 1 and cluster 23
centroid scores across the PDX models into co-expression network (CEN) derived
classical, quasi-basal and basal models paired with Consensus Clustering (k=2) into
Moffitt’s classical and basal subtypes. The heatmap demonstrates the strong
anticorrelation in the cluster enrichment between cluster 1 and 23.
(Left) Pie chart comparison of clinical histology and recurrence of patients associated
with PDX models across CEN subtypes. P values are derived from Chi Square test. The
three pie charts correspond with the breakdown of models into the CEN derived
classical, quasi-basal and basal subtypes.
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To gain further insight into the molecular signatures driving PDAC subtypes, we
conducted gene-set enrichment analysis110 to compare C1vC23 defined classical vs.
basal-like models within our PDX cohort (excluding models described as quasi-basal).
This highlighted that EMT signaling was significantly enriched among PDX models that
fell into the C1vC23 definition of basal-like, whereas this gene set was depleted in
classical models (Figure 3E). Enrichment of an EMT signature in basal-like PDX models
supports the hypothesis that the basal-like subtype is strongly associated with tumors
where a majority of tumor cells has at least partly undergone trans-differentiation towards
a mesenchymal phenotype56,111.

Figure 22: GSEA conducted on PDAC co-expression network-defined classical
and basal-like models identifies EMT as a top pathway enriched in basal-like
models FDR = 0.000.
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4.8: Anticorrelated Signatures Recapitulated in TCGA Samples
Consistently, analysis of clinical and histological data for the PDX cohort
demonstrated that basal-like tumors were uniformly associated with poor differentiation
status and distant metastatic recurrence (Figure 3B). Next, using high-epithelial-content
PDAC patient data from TCGA (30% - 80% epithelial cells), we confirmed the presence
of the network-derived subtyping, again identifying a quasi-basal continuum. Further, we
recapitulated the association between tumor histology and the network-derived subtype
in the TCGA dataset, wherein more poorly differentiated tumors were classified as basallike, with strong enrichment in Cluster 23 gene expression (Figure 3F). By quantitatively
characterizing a quasi-basal population, the C1vC23 differential enables a more precise
definition of the clinically relevant basal-like tumor cohort while also expanding on
associated

molecular dependencies

intervention40.

Moreover,
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differential
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considered

defines
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for

broader,
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characterization of the range of molecular signaling contributing to diversity in PDAC,
which can be used to granularly ascertain pathways that may be therapeutically targeted
to exert anti-tumor effects across this classical, quasi-basal and basal-like tumor
spectrum.
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Figure 23: Prominent anti-correlated clusters identifying “classical”, “quasibasal”, and “basal-like” recapitulated in TCGA.
[left panel] Pie chart comparison of tumor differentiation status in high-epithelial-content
TCGA comparing the two group Moffitt subtype and the co-expression network
anticorrelating cluster 1 and 23 signatures.
[right panel] Heat map of C1vC23 anti-correlated cluster signature differential, matching
Moffitt classification and tumor grade on TCGA tumor samples (samples with ≥ 30%
epithelial content) with models comparing PDAC co-expression network-derived
classifications and Moffitt classifications (n=76 tumors).
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4.9 Discussion
Using our large cohort of PDAC PDX models, we constructed a cell intrinsic PDAC
co-expression network. We applied a Bayesian method, the Log Likelihood Score to
prune our network to not just statistically significant gene-pairs, but also maximize the
likelihood that a given gene-pair is biologically relevant. Using a large network community
detection tool, we also identified 31 unique clusters, which we further GO annotated for
biological function. Interestingly, we identified anticorrelated signatures across two
clusters – cluster 1 and cluster 23. These anticorrelated signatures recapitulated the
Moffitt classical/basal-like subtypes on a continuous spectrum. Further, we were able to
identify a transitionary group of tumors that partially express both cluster 1 and cluster 23.
Using the three-tier classification, we were able to provide improved resolution in clinical
associations with subtypes and consistently identify basal tumors with poor differentiation
status and distant metastases.
Here we are able to demonstrate that the Moffitt classical and basal subtypes are
likely two ends of a subtype continuum, rather than discrete groups. Current
computational methods aiming to classify PDAC tumors into subtypes, regardless of what
the subtypes are, fall short of capturing the granular heterogeneity in tumors due to their
categorical nature. Using the co-expression network in this context provides an avenue
to capture this heterogeneity on a continuous scale, but also categorize these tumors for
ease of further analyses, as we have shown above.
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Chapter 5: Integration of the Co-Expression Network with Single Cell
Transcriptomic Signatures

This work is based on efforts outlined in our recent BioRxiv submission “Diversity
Across the Pancreatic Ductal Adenocarcinoma Disease Spectrum Revealed by
Network-Anchored Functional Genomics” by Rose and Srinivasan, et al. (2020), DOI:
https://doi.org/10.1101/2020.09.17.302034. As co-first author, Dr. Johnathon Rose provided
substantial experimental support for this effort, enabling our findings. The manuscript is
currently under review.
5.1: Interrogating the Quasi-Basal Signature Intratumorally
We have validated the presence of the transitionary, “quasi-basal” subtype in the
bulk PDAC PDX and TCGA samples. This raises the question of the origin of this
signature. Two possibilities exist:
1. The quasi-basal signature identified in bulk tumors is a computational artifact – it
is an average transcriptional signature of competing classical and basal-like
subclones within the tumor.
2. The quasi-basal signature is an additional transitionary state that exists and is
quantifiable intratumorally.
The Toronto classification, part of the COMPASS Trial, also recently provided
clarity on the presence of a hybrid subtype in their bulk sequencing of tumor samples.
These tumors were classified as hybrid due to expressing both the classical and basallike signatures they derived using NMF. Interrogation of the signature intratumorally
confirmed that tumors express both classical and basal-like programs within the same
tumor. This was segregated into different tumor cell subsets within the same tumor42.
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The findings of the Toronto classification suggest that the quasi-basal signature is
an average signature of classical and basal-like subclones. However, given that this
methodology results in categorical subtypes, it is likely that it insufficiently captures the
spectrum of enrichment from both subtype signatures42.
Here we hypothesized that the quasi-basal tumors we characterized in the bulk
samples are a quantifiable state, that can be captured using a more continuous
classification method, and not an artifact of two competing subclonal populations. We
investigated this by applying the PDAC co-expression network anticorrelating C1 and C23
signatures towards single cell analysis, as described below.
5.2: Single Cell Samples Utilized
To investigate whether the quasi-basal signature identified in bulk tumor
populations represents either a quantifiable cell state or a mean signature derived from
competing subcellular populations, we conducted single-cell RNAseq (scRNAseq) on
early-passage cell lines derived from PDX models PATC69 (quasi-basal), PATC124
(quasi-basal), and PATC53 (basal-like). Single-cell samples of PATC124 and PATC53
were courtesy of Dr. Andrea Viale’s lab and cultured, collected and sequenced by Dr.
Chieh-Yuan Li for a prior publication112. Single-cell samples for PATC69 were cultured,
collected and sequenced by Dr. Johnathon Rose. Additionally, in order to evaluate the
utility of the network-defined tumor subtypes in a clinical setting, in which small numbers
of cells and stromal components may influence molecular analyses, we evaluated seven
patient core needle biopsies (CNBs; four primary tumors, as well as one each of liver,
lung, and vaginal metastases) using the network-aided scRNAseq analysis55.
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Specifically, network-aided analysis applied clusters identified in the PDAC coexpression network to address limitations in scRNAseq. This is due to the fact that
genome-wide expression in individual cells is currently not feasible. On average, a single
cell expresses only up to approximately 4000 genes54. Given this, in order to apply our
PDAC co-expression network to single data to capture cluster level centroids, we sought
to adapt the method to apply to a single cell setting.
5.3: Cluster Signatures for Single Cells
Network-based normalization of cluster signatures amongst single cells was
achieved by first identifying a subset of genes whose expression was strongly correlated
with its own cluster assignment (r > 0.4). For the PDX models, using the subset of highly
correlated genes per cluster, if more than 30% of the cluster was captured per single cell,
we calculated a centroid score by taking the mean of normalized UMI count. For patient
CNB samples, centroid was calculated for all single cells if more than 20% of the cluster
was captured. The percentage of cluster genes expressed within each cell type was
calculated by taking the mean number of genes with UMI count above 0 per cluster across
all the single cells within each cell type. The co-expression network was used to identify
cells expressing more than 30% (20% for CNBs) of any cluster, and a centroid score for
that cluster was calculated using genes with expression highly correlated to the cluster
enrichment (r > 0.4).
5.4: Single-cell Transcriptomic Profiles Recapitulate Granularity of PDAC
Subtypes
We applied this method to the PDAC PDX derived cell lines from PATC69,
PATC124 and PATC53. We assigned centroid scores across all 31 clusters from the
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PDAC co-expression network on each single cell on a model by model basis (Figures 2426). A small proportion of single cells across all three models were coded as “NA” if they
did not express enough of the cluster genes as described above. Specifically, we
considered cluster 1 and cluster 23 scores to evaluate if a) a dynamic range in the
enrichment of each cluster exists, b) if the spectrum of enrichment of each cluster is
continuous or discrete (high expression vs. no expression) and c) whether the anticorrelation of the two clusters is present on a single cell scale.
This approach successfully confirmed that similar to the bulk tumors, cluster 1 and
cluster 23 showed dynamic, continuous expression across single cells, and displays the
same anticorrelation. We computed a cluster differential score (cluster 1 – cluster 23) to
quantify the spectrum of enrichment across cluster 1 and 23. Single cells were grouped
into classical, quasi-basal and basal based on the cluster 1 and cluster 23 differential
signature, classified as basal if the differential signature was < -0.1, quasi-basal if they
are -0.1 to 0.1 and classical if they were > 0.1. The results for each of the three samples
is presented in Figures 27-29.
As is evident, even on a single cell scale, we are able to capture single cells that:
a) are enriched in either cluster 1 or 23 and depleted in the other, and b) show equal
enrichment of cluster 1 and cluster 23. As a result, we demonstrate that the quasi-basal
state identified in bulk tumors, also exists as a quantifiable state within single cells. Using
the cluster 1 and 23 differential, the quasi-basal signature is quantifiable state in individual
cells within in each PDX model, confirming that the bulk readout represented an average
of the intratumoral spectrum of classical, quasi-basal, and basal-like sub-clonal
populations, rather than competing classical and basal-like signatures (Figures 27-29).
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Interestingly, quasi-basal single cell analysis also composed the largest proportion
of cells across all three subtypes (Figures 27-29). While this is not surprising in PATC69
and PATC124, quasi-basal tumors in bulk PDX models, it is surprisingly still the case in
PATC53, a basal-like tumor in bulk state (Figure 14, Figure 21). Indeed, PATC53
displayed a large proportion of cells with much higher enrichment of cluster 23 than the
other two models, explaining its classification as a basal-like tumor (Figure 14, Figure 21).
Similarly, PATC69, on a bulk scale showed slightly higher enrichment in cluster 1 than
23, despite being classified as quasi-basal (Figure 21). Accordingly, PATC69 displayed
the largest proportion of single cells that were classified as classical along with higher
expression of cluster 1 compared to the other two models (Figure 27). This is also
demonstrated in the density plot with the distribution of single cells across the highly
negative (enriched in cluster 23) to near 0 (partial enrichment in both clusters) and highly
positive (enriched in cluster 1) cluster differential scores (Figure 30). This displays a
statistically significant difference in this distribution across all three models (Kolmogorov
Smirnov test, p < 2.2e-16) (Figure 30). Thus, in similar fashion to the COMPASS trial42,
we also validated that all three of the models encompass both classical and basal
subtypes, while also demonstrating that quasi-basal cells co-expressing both programs
exist intratumorally (Figure 27-30).
We also applied the Moffitt classical and basal-like classification towards the single
cell analysis of PDX cell lines, using consensus clustering to all three models. Here, we
assigned Moffitt subtypes to single cells using a method called Nearest Template
Prediction (NTP)113. Using a set of template genes, the previously defined classical and
basal-like gene sets released by Moffitt, et al, the NTP algorithm makes a class prediction
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using a sample’s gene expression based with an accompanying p value as a confidence
measure of the prediction. In the case of PATC69 and PATC53, we find that no single
cell is classified into a subtype with p < 0.05. Within PATC124, the majority of single cells
were classified under NTP – all as basal, including single cells that showed high
enrichment of cluster 1 and low enrichment of cluster 23 (Figures 24-26).
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Moffitt
CEN

Figure 24: Heatmap of centroid expression of all 31 clusters of the PDAC coexpression network in PATC69 single cells.
Centroid expression of 31 clusters computed from single cells that meet the quality control
thresholds. Single cells in grey represent cells that did not meet this threshold. The top
annotation bar represents the Moffitt subtype, calculated using NTP. Annotation bar in
grey represents cells that were not classified at p < 0.05. The bottom annotation bar
represents the subtype determined by the co-expression network (CEN), with blue
representing the classical subtype, beige representing quasi-basal subtype, and orange
representing the basal subtype.
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CEN

Figure 25: Heatmap of centroid expression of all 31 clusters of the PDAC coexpression network in PATC124 single cells.
Centroid expression of 31 clusters computed from single cells that meet the quality control
thresholds. Single cells in grey represent cells that did not meet this threshold. The top
annotation bar represents the Moffitt subtype, calculated using NTP. Annotation bar in
grey represents cells that were not classified at p < 0.05, and orange represents the basal
subtype. The bottom annotation bar represents the subtype determined by the coexpression network (CEN), with blue representing the classical subtype, beige
representing quasi-basal subtype, and orange representing the basal subtype.
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CEN

Figure 26: Heatmap of centroid expression of all 31 clusters of the PDAC coexpression network in PATC53 single cells.
Centroid expression of 31 clusters computed from single cells that meet the quality control
thresholds. Single cells in grey represent cells that did not meet this threshold. The top
annotation bar represents the Moffitt subtype, calculated using NTP. Annotation bar in
grey represents cells that were not classified at p < 0.05. The bottom annotation bar
represents the subtype determined by the co-expression network (CEN), with blue
representing the classical subtype, beige representing quasi-basal subtype, and orange
representing the basal subtype.
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Figure 27: Cluster 1 and 23 differential in PATC69 reveals quasi-basal single cells.
(Top) UMAP of single-cell PATC69 (7,857 cells), cell line with an overlay of a PDAC coexpression network-normalized cluster 1 and cluster 23 signature differential
(Bottom) Respective percentages of cells corresponding to each subtype where orange
represents the percentage of basal cells, blue represents the percentage of classical cells
and beige represents the percentage of quasi-basal cells.
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Figure 28: Cluster 1 and 23 differential in PATC124 reveals quasi-basal single
cells.
(Top) UMAP of single-cell PATC124 (9,482 cells), cell line with an overlay of a PDAC coexpression network-normalized cluster 1 and cluster 23 signature differential
(Bottom) Respective percentages of cells corresponding to each subtype where orange
represents the percentage of basal cells, blue represents the percentage of classical cells
and beige represents the percentage of quasi-basal cells.
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Figure 29: Cluster 1 and 23 differential in PATC53 reveals quasi-basal single cells.
(Top) UMAP of single-cell PATC124 (14,791 cells), cell line with an overlay of a PDAC
co-expression network-normalized cluster 1 and cluster 23 signature differential
(Bottom) Respective percentages of cells corresponding to each subtype where orange
represents the percentage of basal cells, blue represents the percentage of classical cells
and beige represents the percentage of quasi-basal cells.

98

KS Test: p-value < 2.2e-16

Figure 30: Difference in the distribution of cluster 1 and cluster 23 enrichment
across three PDAC PDX models.
Density histogram of the C1v23 signature differential distributions of PATC124, PATC53,
and PATC69 PDX lines, with more positive cluster differential indicating enrichment in
Cluster 1 and more negative cluster differential indicating Cluster 23 enrichment.
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5.5: Application of the Co-Expression Network in Single-cell Transcriptomic
Profiles from Clinical Samples
To evaluate the utility of the network-defined tumor subtypes in a clinical setting,
in which small numbers of cells and stromal components may influence molecular
analyses, we evaluated seven patient core needle biopsies (CNBs; four primary tumors,
as well as one each of liver, lung, and vaginal metastases) using the network-aided
scRNAseq analysis55 (Figure 31). We first defined the distribution of cell types amongst
our samples (Figure 32) using previously annotated marker genes (Figure 33) (see
methods).
Up until this point, owing to the use of our PDX models, we have not characterized
the expression of the PDAC co-expression network where microenvironment is heavily
present. Our aim with the clinical single cell expression from CNB samples is two-fold. By
evaluating a clinical sample with single cell sequencing, we are able to a) Deconvolute
the signature derived from the epithelial tumor cell compartment from the
microenvironment to assess if the signal is truly tumor cell intrinsic and b) Evaluate the
feasibility of capturing network cluster level expression and the granular distribution of the
Moffitt subtypes.
To deconvolute the signature derived from the epithelial tumor from the
microenvironment, we first divided our first annotated and grouped our cells by cell type,
as described above. Then, on for all the cells from a single cell type, we computed the
proportion of genes from each cluster of the co-expression network that showed any
expression (UMI > 0). We characterized cluster representation across the tumor
microenvironment by quantifying the mean proportion of genes of each cluster for each
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cell type. This identified the epithelial component of the tumor as the primary contributor
to the co-expression network cluster signatures (Figure 34).
Next, applying the same cluster centroid normalization method described above
for CNBs, the majority of cells that met our quality control cutoff were epithelial cells, with
very little representation from two primary tumor samples (Primary 1 and Primary 2) that
contained little to no epithelial content (Figure 32). Finally, to determine where each cell
type was represented on the classical to basal-like continuum, we assessed the C1vC23
cluster differential. We found that the C1vC23 classification is largely present within
epithelial cells, with Uniform Manifold Approximation and Projection (UMAP) clusters of
fibroblasts and endothelial cells only representing a minority of misclassified C1vC23
signatures within the representative multiregional tumor microenvironment (Figure 35).
This finding confirms a lack of sample purity bias in the characterization of C1vC23
signatures in the TCGA PDAC samples (Figure 23) and supports the feasibility of applying
network-based cluster characterization to bulk clinical samples, including CNBs.
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Figure 31: Diagram of the locations and numbers of isolated patient core needle
biopsy (CNB) samples used for single-cell RNA sequencing analysis.
A total of 4 primary samples were obtained (3 from female patients, and 1 from a male
patient), along with three metastatic samples (one liver and lung sample each from male
patients, and one vaginal metastasis from a female patient).
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Figure 32: UMAP outlining the tumor microenvironment components of multiple
single-cell sequenced primary (n = 4) and metastatic (n = 3) CNB samples from
PDAC patients.
UMAPs of 25,954 single cells separated by the seven patient core needle biopsies. P1p4 represents primary tumor samples. LiM represents the liver metastasis sample, LuM
represents the lung metastasis sample and VM represents the vaginal metastasis
sample. Analysis was performed using Seurat 3.1 and clusters were identified using a
resolution of 0.2.

104

105

106

Figure 33: Expression of known marker genes was used to identify cell type of
each UMAP-identified cluster.
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Figure 34: Representation of the PDAC co-expression network genes across cell
types in PDAC patient core needle biopsy samples (n=7).
The mean percentage of cluster representation for each cluster in the PDAC coexpression network from the cellular constituents of the tumor microenvironment. Each
dot per cell type represents individual clusters. Box plot center: mean; box: quartiles 1–3;
whiskers: quartiles 1–3 ± 1.5 × IQR.
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Figure 35: Combined CNB UMAP with an overlay of a PDAC co-expression
differential signature of cluster 1 and cluster 23 expression.
UMAP of seven single-cell CNB samples (25,954 cells), with an overlay of a PDAC coexpression network-normalized cluster 1 and cluster 23 signature differential where
orange represents the percentage of basal cells, blue represents the percentage of
classical cells and beige represents the percentage of quasi-basal cells, and grey
represents cells that did not meet the minimum threshold of PDAC co-expression genes
expressed to have a cluster centroid score.
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5.6: Discussion
Previous reports of a hybrid subtype on the bulk scale have been classified as an
average

signature

of

competing

classical

and

basal-like

subtypes

existing

intratumorally42. Here, we validated the quasi-basal subtype observed in bulk samples as
a quantifiable state in single cells as well. The partial enrichment of cluster 1 and cluster
23 in the bulk tumors is not as a result of single cells separately expressing cluster 1 or
23 intratumorally. However, on a single cell scale, across three models, we demonstrate
that single cells also show equal enrichment of cluster 1 and 23. Again, we demonstrate
that the cluster 1 and 23 anticorrelation is a continuous spectrum in our PDAC PDX
derived cell lines.
We also investigated the expression of the co-expression network clusters in
clinical grade samples from primary and metastatic patients. Using clinical patient allows
us to characterize how different components of the PDAC microenvironment influences
the co-expression network signatures we observe. Using our network normalized cluster
enrichment method described above, we were able to confirm that the majority of the
signature arises from the tumor epithelial component, confirming that the co-expression
network is highly cell intrinsic.
By analyzing scRNAseq data in the context of the co-expression network, we
circumvented the technical issue of signal dropout by prioritizing large gene clusters to
represent transcriptional diversity rather than single gene expression. Thus, the coexpression network serves as an additional resource for disease-specific single cell
analysis.
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Chapter 6: Intratumoral Validation of Functional Vulnerabilities with CoExpression Network

This work is based on efforts outlined in our recent BioRxiv submission “Diversity
Across the Pancreatic Ductal Adenocarcinoma Disease Spectrum Revealed by
Network-Anchored Functional Genomics” by Rose and Srinivasan, et al. (2020), DOI:
https://doi.org/10.1101/2020.09.17.302034. As co-first author, Dr. Johnathon Rose provided
substantial experimental support for this effort, enabling our findings. The manuscript is
currently under review.

6.1: Integration of CRIPSR Identified Dependencies with the Co-Expression
Network
The distinct gene clusters we identified in the PDAC co-expression network
provide a means to deeply characterize the diversity of any PDAC model by considering
correlations in disease-specific cluster enrichment patterns, a parallel strategy to current
approaches that use consensus clustering to assign a tumor subtype based on refined
PDAC-specific gene sets. Thus, this refined co-expression network can comprehensively
quantify global transcriptomic signaling trends on a tumor-by-tumor basis.
As previously reported, we interrogated the dependencies identified through our in
vivo CRISPR screens in three models, PDX derived cell lines PATC69 and PATC124
(quasi-basal) and PATC53 (basal). Next, we integrated quantile-normalized BFs obtained
from each screen with the PDAC co-expression network to generate dependency
networks for each model (Figure 36). The in vivo PATC53 dependency network
highlighted multiple unique groups of interconnected vulnerabilities when compared to
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PATC69 and PATC124 dependency networks, despite PATC53 and PATC124 both being
classified as basal-like, based on the Moffitt signature (Figure 14). Notably,
interconnected vulnerabilities in PATC53 were associated with epithelial-to-mesenchymal
transition (EMT) (e.g. SNAI1, ZEB1, SMAD4, MAPK11 and MAPK14), integrin signaling
(e.g. ILK, ITGB1, ITGB2 and NPNT), heparan sulfate proteoglycan regulation (e.g. SDC3
and EXT1), cell junction regulation (e.g. CTTN, TJP1 and TJP2) (Figure 36).
The integration with the co-expression network also displayed a clear shift in the
PATC53-associated dependency spectrum along the cluster 1 -to- cluster 23 axes, with
many of the dependencies identified in the CRISPR screen localized within, or adjacent
to, cluster 23 (Figure 36). Specifically, MAPK11 and FAM171A2 were localized within
cluster 23 itself; NKAIN4 in Cluster 25; and SMAD4, ZEB1 and SDC3 in cluster 31, which
exhibits high correlation with cluster 23 expression (Figure 17). The network localization
of functionally annotated and PATC53-specific ZEB1, an EMT-associated transcription
factor, and SMAD4, an EMT facilitator and oncogenic driver in advanced PDAC,
implicated a connection between the cluster 1 to 23 axis, and its associated
dependencies, with PDAC epithelial-to-mesenchymal transdifferentiation114,115.
By integrating CRISPR screen-defined co-dependencies with the co-expression
network, we were able to identify both common and unique dependencies within the
larger context of PDAC diversity (Figure 9). As demonstrated in the previous chapter,
single cell expression of the same three PDX derived cell lines, PATC69, PATC124 and
PAT53 demonstrates a vast degree of intratumoral heterogeneity.
To address this, we developed an experimental platform to conduct a small scale,
direct-capture PerturbSeq116. Using two PDX derived cell lines, PATC69 and PATC53,
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we knocked out four genes in an arrayed fashion – one negative control and three
hypothesized basal cell dependencies. The objective of this approach was to integrate
our approaches (the CRISPR knock-out screening, PDAC co-expression network derived
signatures, and network normalized cluster signatures applied to single cell sequencing)
to demonstrate that the unique dependencies we identified in our CRISPR screening in
PATC53 do represent functional dependencies of the basal subtype. Conversely, this
approach also provides an opportunity to study these transcriptional signatures in the
context of targeted gene perturbation, as opposed to mainly focusing on correlation with
clinical features. Given the intratumoral subtype heterogeneity we have described in our
models, we sought to validate if these basal vulnerabilities preferentially impacted only
basal single cells. Since the quasi-basal cells show partial expression of both cluster 1
and cluster 23, we sought to evaluate the impact that these gene knock-outs has on this
specific population of cells.
We evaluated the effect of perturbing gene targets associated with the basal-like
subtype that were prioritized through the integration of the CRISPR screening hits with
the co-expression network in varied tumor contexts (schematic presenting the general
experimental overview is presented in Figure 36). Based on our in vitro CRISPR
screening results, we selected sgRNA sequences targeting SMAD4, ZEB1, and ILK, as
well as the non-essential gene, ABCG8, as a negative control. The CRISPR-defined
dependencies in PATC53 SMAD4 and ZEB1, both localized within the network, were
targeted for cluster 1 to cluster 23 signature validation. ILK, a CRISPR-defined
dependency in PATC53 not present in the co-expression network, was selected to
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determine whether knockout of this potential EMT regulator would also have the capacity
to influence this signature differential117-119.
We applied a feature barcoding strategy where a complement sequence was
incorporated into the 3’ end of the sgRNA sequences, enabling scRNAseq sample
multiplexing and quantification of the C1vC23 signature shift relative to the sgABCG8
negative control distribution (see methods for details). Individual sgRNAs derived from
the CRISPR library were transduced into quasi-basal PATC69 and basal-like PATC53
cells. Cells were cultured cells in vitro and collected at the earliest point when separation
of essential versus non-essential genes was observed in the original CRISPR screen
(Day 20). Sanger sequencing was used to analyze the indel frequency of each sgRNA
and colony growth was tracked for each sgRNA to confirm selective growth inhibition in
the basal-like PATC53. Multiplexed scRNAseq was conducted on 10,000 cells total
(2,500 cells per sgRNA) for each PDX line model. This experiment was conceptualized,
designed and conducted by Dr. Johnathon Rose, co-first author on this manuscript.
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Figure 36: Co-expression network anchoring of in vivo functional dependencies
on a model by model basis.
Overlay of context essential genes is represented as quantile-normalized Bayes Factors
(BFs), to inform on cluster-associated vulnerability context in PATC69, PATC124, and
PATC53 PDX lines. The size of the gene represents the magnitude of the BFs in each
screen.

117

118

Figure 37: Overview of the feature barcoding strategy for intratumoral tracking of
PDAC co-expression network signatures following sgRNA knockouts.
Targeting sgRNAs for ABCG8 (as a negative control), ILK, SMAD4, and ZEB1 were
selected and based on CRIPSR screening results. PATC69 and PATC53 cell populations
were individually transduced in vitro, selected with puromycin, and parallel assays were
also prepared to confirm knockout phenotypes through colony growth, and sgRNA cutting
through Sanger sequencing. Each knockout cell population was cultured in vitro for 22
days (CRISPR screening time-point day 10), and then combined scRNAseq library
preparation. A total of 10,000 cells per PDX line were sequenced, 2,500 per condition
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6.2: Analysis of the Feature Barcoded scRNAseq Validates Subrype Specific
Functional Vulnerabilities
Feature barcoded scRNAseq data were analyzed using Seurat3.154. Each cell line
was individually evaluated. Cells expressing more than 350 genes and less than 25%
mitochondrial reads were retained and subsequently log normalized, variant stabilized,
and total RNA count, mitochondrial reads and cell cycle were regressed out. All guidelevel samples for each PDX line were merged using the Seurat Anchor Cell feature to
provide a direct point of comparison for PATC69 and PATC53 perturbations. A total of
10,113 PATC69 (3449 ABCG8, 1962 ILK, 2662 SMAD4, and 2040 ZEB1 knockout cells)
and 11,439 PATC53 (3414 ABCG8, 2952 ILK, 2819 SMAD4, and 2254 ZEB1 knockout
cells) cells were retained and analyzed for processing. Principal-component analysis and
UMAP with the first 20 dimensions was performed, with clustering performed at 0.15
resolution for. Cluster centroids were calculated using the method described above for
the patient CNB samples.
PATC69 UMAPs revealed that the knockout conditions did not perform any
differently than the ABCG8 negative control (Figure 38). Single gene knock-outs also
displayed no differences in cell viability between ABCG8 and any of the knockout
conditions. In contrast, PATC53 UMAPs revealed a clear separation between the ABCG8
negative control knockout cells and populations with perturbations in combined cluster 23
(SMAD4 and ZEB1) and basal-like (ILK)-associated genes (Figure 39). Also, as expected,
the PATC69 population transduced with negative control sgABCG8 contained coexpression defined classical and quasi-basal cells, with very few basal cells (Figure 40).
The basal-like PATC53 population contained quasi-basal and basal-like cells in the
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population transduced with the negative control ABCG8, with little to no classical cells in
this population (Figure 40).
To test the cluster 1 to cluster 23 signature distribution shift relative to the reference
distribution defined by the ABCG8-null negative control, cluster 1 to cluster 23 density
plots were generated for each sgRNA knockout cell line (Figure 41), and Kolmogorov’s D
statistic was used. Deletion of ILK, SMAD4, and ZEB1 each resulted in a significant
cluster 1 to cluster 23 shift towards the cluster 1-enriched classical signature in both
PATC69 (Figure 41) and PATC53 (Figure 42). In parallel with scRNAseq, transduced
populations were seeded in vitro immediately following selection to compare relative
growth phenotypes for both PDX lines (Figure 37). Coinciding with the signature shift
towards cluster 1 at the single-cell level, perturbation of each of the three basal-likeassociated genes inhibited bulk population growth in PATC53 relative to sgABCG8knockout controls (Figure 38), whereas no growth phenotype was observed in the
classical PATC69 (Figure 38).
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Figure 38: Comparison of ILK, SMAD4, and ZEB1 knock-outs to negative control
ABCG8 conditions in PATC69.
(Top) UMAP of the PATC69 PDX line with defined ABCG8, ILK, SMAD4, and ZEB1
knockout populations (10113 total cells).
(Bottom) Normalized viability of PATC69 cells following knockout of ABCG8, SMAD4,
ZEB1, ILK, or RPS27A with sgRNA. **p < 0.05.
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Figure 39: Comparison of ILK, SMAD4, and ZEB1 knock-outs to negative control
ABCG8 conditions in PATC53.
(Top) UMAP of the PATC53 PDX line with defined ABCG8, ILK, SMAD4, and ZEB1
knockout populations (11,439 total cells).
(Bottom) Normalized viability of PATC53 cells following knockout of ABCG8, SMAD4,
ZEB1, ILK, or RPS27A with sgRNA. **p < 0.05.
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Figure 40: UMAPs detailing the cluster 1 and cluster 23 signature in each singlecell RNA sequenced for PATC69 (top) and PATC53 (bottom).
(Top) UMAP of PATC69 with all four knock-out conditions, with an overlay of a PDAC coexpression network-normalized cluster 1 and cluster 23 signature differential where
orange represents the percentage of basal cells, blue represents the percentage of
classical cells and beige represents the percentage of quasi-basal cells, and grey
represents cells that did not meet the minimum threshold of PDAC co-expression genes
expressed to have a cluster centroid score.
(Bottom) UMAP of PATC53 with all four knock-out conditions, with an overlay of a PDAC
co-expression network-normalized cluster 1 and cluster 23 signature differential where
orange represents the percentage of basal cells, blue represents the percentage of
classical cells and beige represents the percentage of quasi-basal cells, and grey
represents cells that did not meet the minimum threshold of PDAC co-expression genes
expressed to have a cluster centroid score. The red box represents the population of
ABCG8 knock-out cells, which cluster separately from the other knock-out conditions.
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Figure 41: Comparative PATC69 density plots of cluster 1 and cluster 23
signature following knockout with sgILK, sgSMAD4, sgZEB1 and sgABCG8.
Differential is calculated as the differential between the Cluster 1 and 23 centroid score,
with more positive differential indicating cluster 1 enrichment and more negative
differential indicating cluster 23 enrichment. P values and D statistic derived from
Kolmogorov Smirnov test
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Figure 42: Comparative PATC53 density plots of cluster 1 and cluster 23
signature following knockout with sgILK, sgSMAD4, sgZEB1 and sgABCG8.
Differential is calculated as the differential between the Cluster 1 and 23 centroid score,
with more positive differential indicating cluster 1 enrichment and more negative
differential indicating cluster 23 enrichment. P values and D statistic derived from
Kolmogorov Smirnov test
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6.3: Discussion
In summary, we provide functional validation of the cluster 1 and 23 signature
based on concordant signature shifting, in both quasi-basal PATC69 and basal-like
PATC53 cell populations, following genetic perturbation of basal-like associated targets.
Importantly, these findings provide evidence for our platform to uncover the intratumoral
context of vulnerabilities localized within and adjacent to cluster 23, by quantifying the
targeted depletion of cluster 1 and cluster 23 defined basal-like cell populations. This
represents a novel approach to leverage network-informed signaling perturbation to
influence heterogeneity in pancreatic tumors.
In PATC69, given that there is little to no basal population of cells within the
negative control, we cannot speak to the impact of the gene knock-outs on this population.
However, it is of note that there is a statistically significant shift towards a positive
differential in all three conditions compared to the negative control. This suggests that
these identified basal dependencies, predictably do not have an impact on the classical
cell population. Surprisingly, knock-out of these basal markers resulted in decreased
density of quasi-basal cells, suggesting that in addition to partially expressing both cluster
1 and 23 markers, the quasi-basal population may show partial essentiality to basal
dependencies.
This is further supported when we consider PATC53. As expected, the negative
control condition in PATC53 displays a proportion of single cells with enrichment in cluster
23. In each of the three knock-out conditions, we see that there is large shift towards the
right in these distributions, possibility due to preferential death of basal cells in PATC53.
Similar to PATC69, there is an overall shift towards the right of the quasi-basal population
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as well. In the negative control condition, there are no cells enriched for cluster 1.
However, in all three knock-out conditions, there is an outgrowth of classical cell
populations. Given there is no population of cells with classical enrichment in the negative
control, it is unlikely that this outgrowth in the knock-out conditions is a result of
competition.
This collectively suggests that the quasi-basal population demonstrates some
degree of plasticity and is capable of reverting to a classical state in the absence of
essential basal dependencies.
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Chapter 7: Discussion and Future Directions
A disease characterized by a relatively flat mutational landscape, a dense
desmoplastic stroma, adaptive chemoresistance and poor patient prognosis, Pancreatic
Ductal Adenocarcinoma (PDAC) persists as a major clinical challenge with limited
therapeutic opportunity1,3,12. Despite major clinical efforts through efforts like the phase III
POLO trial, establishing clear survival advantage through patient stratification and
targeted therapy remains elusive37,38. Recent efforts have sought to expand PDAC
stratification efforts into transcriptomic landscape, starting with Moffitt, Collison and Bailey
identifying concordant and tumor-intrinsic classical and basal-like subtypes43. These
subtypes were then subsequently expanded upon, identifying transitory hybrid groups42.
However, while these subtypes are reflective of elements such as patient prognosis and
tumor differentiation status, they have yet to inform on underlying genetic dependencies
of these tumors.
Advancements in CRISPR-Cas9 functional genomics, tumor modeling, and nextgeneration sequencing (NGS)66,67,69 are providing opportunities to better understand
disease diversity and genetic dependency for PDAC. In order to take full advantage of
these advancements, computational methodology to properly utilize these resources
need to be innovated. Here, I developed and implemented several methodologies critical
for: a) deciphering pooled customized sgRNA libraries for pancreatic tumors modeled in
vivo, b) leveraging RNA sequencing data derived from a PDAC PDX cohort, and c)
analyzing single-cell sequencing data in pancreatic tumor models and patient biopsies.
The overarching purpose of these computation efforts being to anchor genetic
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dependencies within the context of signatures underling PDAC transcriptomic diversity,
with a focus on combining tumor modeling and functional genomics.
Low-Fat BAGEL and in vivo Genetic Screens
As previously described, Low-Fat BAGEL was adapted to maximize guide level
data from smaller training sets while employing a linear regression model to decrease the
impact of outliers. In doing so, this approach allowed for a more accurate classification of
controls, which in turn provided more confidence in the accuracy of essentiality
determined for the remainder of the expanded surfaceome library. Applying Low-Fat
BAGEL to small custom libraries allows for optimized screening in vivo. Leveraging this
analysis allowed for a refined comparison of dependencies across multiple PDAC PDX
cell lines in vivo, highlighting unique and common vulnerabilities and informing on the
oncogenic signaling driving these tumors.
Future utilization for Low-Fat BAGEL also has potential for screening custom
libraries in organoid settings, or even in direct PDX screening. This Bayesian approach
for library analysis also has the potential to be expanded beyond the scope of targets that
influence gene proliferation alone. For example, establishing a set of essential and nonessential controls within the context of transcriptional reporter activity could have the
potential for a refined analysis, and expansion, of prominent biological pathways. For
example, utilizing gene targets whose knockout enhances signaling/reporter activity vs.
gene targets whose knockout represses signaling/reporter activity as a training set.
Moreover, expanding Low-Fat BAGEL analysis for screens conducted in a syngeneic
setting may provide further insight into tumor dependencies within the context of an active
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immune systems, assuming random dropout of the implanted tumor population is largely
negligible in this case.
PDAC Co-Expression Network Development and Applications
Efforts in transcriptomic subtyping efforts have largely been applied through NMF
using patient samples with high epithelial content or using a virtually microdissected
dataset to limit influence from stroma40. While these gene sets are refined using patient
data, and have prognostic relevance, this subtyping approach provides an inherently
categorical stratification of tumors while primarily only focusing on the most prominent
transcriptomic differences between essentially two groups. Development and refinement
of a PDAC co-expression network utilizing LLS95, and subsequent annotation of highly
interconnected gene clusters using InfoMap96 and GO98, served as an orthogonal
approach to identify clusters of genes that contribute to transcriptomic diversity within the
PDAC PDX cohort. Observation of cluster patterns individually, while providing
dimensional reduction to the PDAC transcriptome, initially only highlighted a high level of
heterogeneity across the cohort of PDXs. However, when observing cluster patterns
within the context of each other, clear anticorrelating signatures pointed towards multiple
clear transcriptomic shifts contributing to PDAC diversity. These patterns prominently
focused around two anticorrelating gene cluster pairs, cluster 1 vs. cluster 23, and cluster
2 vs. cluster 13. Leveraging these anticorrelating clusters to establish a differential
signature to characterize the disease spectrum, capturing transitioning transcriptomic
states as a spectrum as oppose to leveraging NMF to categorically bin the disease into
discrete groups. This is relevant as the cluster 1 vs. cluster 23 differential signature, along
with enriching clinical features such as site of tumor reoccurrence and tumor
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differentiation status, is highly enriched for epithelial-to-mesenchymal transition (EMT),
based on GSEA. Thus, there is an argument to leveraging a differential signature to
characterize disease-specific EMT patterns as a spectrum, as this is more representative
of the progressive alterations in transitioning cells. In addition, these larger gene clusters
provide a broader interpretation of transcriptional patterns underlying both sides of the
transitory spectrum. Additionally, leveraging clusters co-expressed with cluster 23 can
serve to provide additional interpretation in models already enriched for cluster 23.
This network model also served as a tool to characterize heterogeneity at the
single cell scale. scRNAseq analysis of PDAC PDX models recapitulated findings from
bulk tumors, revealing vast intratumoral heterogeneity and a cluster-defined classical to
basal-like clonal spectrum with a discrete quasi-basal signature in individual cells. We are
able to demonstrate that the quasi-basal subtype that we have identified is a quantifiable
state in single cells, and form the majority of cells in all of the models we tested.
Furthermore, scRNAseq of patient samples recapitulated that the cluster 1 and 23
anticorrelated signatures present as an intratumoral spectrum, revealing that the majority
of the co-expression network signatures are intrinsic to tumor cells, with limited
confounding noise from the microenvironment. The main exception here being a overrepresentation of cluster 13 across the majority of cell types within the PDAC tumor
microenvironment.
There is potential for further refinement of the co-expression network.
Incorporation of more models can provide greater granularity of co-expressed gene pairs.
Additionally, with ongoing trials like COMPASS and POLO, access to omics data directly
from patients rather than tumor models is becoming more feasible. As always, cell lines
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can also provide an additional source of data. Using the current co-expression network
as a foundation, we can construct parallel networks to begin comparing similarities and
differences in patterns of co-expression between cell lines, PDXs and patients. By doing
this, we can prioritize gene-pairs and clusters that are reinforced in patient datasets, and
identify if cell lines and PDXs can serve as adequate representations of the disease.
PDAC is a disease characterized by vast epigenetic alterations and DNA damage. While
we did not find strong or overarching associations between mutational signatures and
cluster enrichment, there can be utility in exploring other sources of data such as proteinprotein interactions, copy number alterations, and epigenomics. Incorporating data from
RPPA or mass spectrometry, whole genome sequencing, ChIP-seq, ATAC-seq, DNA
methylation, etc. can serve as additional layers to the co-expression network – essentially
“activating” or “strengthening” certain gene pairs. Another interesting avenue to consider
is applying the co-expression network to spatial transcriptomics. We can incorporate data
from emerging technologies, such as slide-seq120, to evaluate if co-expressed genes and
clusters that are also colocalized. We can begin to elucidate if the transcriptional
heterogeneity that we describe intratumorally is spatially localized, or if we identify a wider
pattern of subclonal distribution across a tumor sample.
The PDAC co-expression network, and this analytical approach have provided a
mechanism for us to capture the diversity in transcriptional signaling in a comprehensive
manner. This platform is also malleable with potenital scope for further refinement across
many fronts based on the specific hypotheses at hand.
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Linking Genetic Dependency with Network-based Transcriptomic Signatures
Recently, the Viale lab at MD Anderson have evaluated tumor evolution and
heterogeneity in PDAC within some of the same models we have utilized in this our work
(PATC124 and PATC53, quasi-basal and basal like, respectively). They have developed
a clonal barcoding technology (CRT) wherein cohorts of PDX tumor derived clones are
barcoded, and followed through time and with different treatment modalities, both in vivo
and in vivo112. They concluded that tumors display a high degree of intratumoral
heterogeneity, which reach an equilibrium over time if left unchallenged by selection
pressures112. Of note, when they treated their barcoded tumors with gemcitabine, they
identified subsets of clones sensitive and resistant to treatment. Moreover, while tumor
size and viability were impacted upon treatment to gemcitabine, attenuation of the
treatment lead to regrowth and relapse90. Together this suggests that tumors consist of
heterogenous subclones that are plastic in nature and are able to reach a new equilibrium
upon selection pressures such as chemotherapy – explaining the general chemoresistant
nature of PDAC112. Similarly, the COMPASS trial found that early stage tumors were more
likely to belong to the classical A/B subtypes, while stage III and IV tumors were more
likely to be basal A/B, with previously reported resectable tumors classified as basal-like,
typically being classified by COMPASS as hybrid. They also found that resectable tumors
classified as basal A/B or hybrid were highly aggressive, and advanced stage basal A/B
were resistant to both gemcitabine and FOLFIRINOX treatment42.
Our work with the feature barcoding system supports the conclusion that these
tumors are highly heterogenous. Specifically, the quasi-basal subclonal population that
we characterize displays a degree of cellular plasticity. As a result of selection pressures,
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here, depleting identified basal dependencies, these subclones are possibly reaching a
new equilibrium by reverting to a classical state in order to survive. We can infer from this
that patients that present in clinic, even at early or resectable stages, likely present with
highly heterogenous tumors that harbor subclones along the entire spectrum of the cluster
1 to 23 subtype continuum. Initial successful treatment response observed in the clinic,
especially with adjuvant chemotherapy, likely impacts the sensitive classical subclones
within the tumor, leading to initial regression of tumor, or at least reduction in tumor size.
However, based on our observations, it is possible that while the classical subclones are
effectively depleted with gemcitabine or FOLFIRINOX, again, the quasi-basal subclones
are able to adapt to a more basal state to survive. As the surviving tumor subclones reach
a new equilibrium, there is increased opportunity for the smaller surviving populations of
basal and quasi-basal to outgrow and vastly outnumber the classical subclones,
explaining why relapsed tumors are often extremely chemorefractory. This highlights the
importance of future studies and clinical assessment focusing on tumor heterogeneity.
Focusing equally on how clonal dynamics are impacted as a result of treatment, rather
than just tumor size and shrinkage might yield more successful treatments long term, and
improve overall survival.
Future directions and expansion of our work can provide further insight into this
possibility by specifically testing for it. Adapting the CRT platform developed by the Viale
lab, we can track individual subclonal populations over time and treatment. With
combined knock out of basal dependencies, we can invariably confirm if the shift to a
more classical state is due to cell death of the basal and quasi-basal populations or
cellular plasticity. Substituting gene knock-out with gemcitabine treatment, combined with
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our co-expression network-based cluster enrichment, we can evaluate if the surviving
populations confirm our hypothesis – that classical cells are preferentially depleted, while
quasi-basal cells adapt to a more basal state, leading to an outgrowth of this population.
Additionally, we can also evaluate the impact of multi-gene knockout, both sequentially
and simultaneously. By knocking out multiple genes that represent classical and basal
dependencies, we can utilize the barcoding approach to evaluate the impact on the quasibasal population to provide more insight into the nature of its adaptability and plasticity.
Taken together, our work suggests that both interpatient and intra-patient
heterogeneity need to play a bigger role in pancreatic cancer research and treatment.
Especially in the development of targeted therapy, patient and model stratification is
essential to ensure that we identify ideal treatment regimens based on transcriptional and
mutational signatures. In addition to this, future research into pancreatic cancer should
focus on the intratumoral impact of perturbation or treatment and evaluate the impact of
sequential or simultaneous combinatorial treatment to specifically target different
populations of subclones, rather than temporarily perturb the equilibrium of specific
subclones.
Conclusions
This

dissertation

presents

computational

efforts

developed

to

quantify

transcriptional and functional heterogeneity within PDAC. While all of these approaches
were custom developed to address specific avenues within our interest in pancreatic
cancer research, they are applicable outside of this context as well.
1. Low-Fat BAGEL can be and is utilized for targeted library CRISPR screens in any
context.
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2. The PDAC co-expression network can serve as a hypothesis generating tool, as a
platform to interrogate model by model transcriptional heterogeneity, and provide
context for other vulnerabilities or single genes, as we have done. The network
methodology in general can also be applied to other model systems, cancers, and
diseases and can be easily tailored to addresses the unique constraints of each
context.
3. Applying the network-based cluster enrichment methodology to single cell samples
allows for interrogation of higher-level gene sets within a system where noise and
signal drop out are still a technical concern.
4. Applying a combined gene knock-out and scRNAseq methodology with
accompanying computational methods to assess the transcriptional impact of gene
knock-out opens the doors for testing various hypotheses that can provide
additional insight into gene dependencies beyond that of cell death.

In sum, the work presented in this dissertation has provided further insight into the
budding field of pancreatic cancer subtyping and characterization, while also contributing
to the field of computational biology and bioinformatics through development and further
refinement of novel methodologies.
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